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Abstract 
 
Background Maternal diet and gestational diabetes have important implications for 
offspring health and disease. The fat mass and obesity associated gene (FTO) has the 
strongest relationship to increased body fat mass in humans, potentially via its effect 
on appetite and insulin sensitivity. Leptin plays a key role in regulating energy intake 
and expenditure, including appetite and hunger. Our hypothesis was that the 
expression of the Fto and leptin gene is influenced by the quality of carbohydrate in 
the maternal diet. Specifically, we postulated that the expression of Fto gene in the 
hypothalamus of the offspring of high glycaemic index (GI) diet-fed mothers would 
be higher than that of low GI diet-fed mothers, whereas the opposite would be 
observed for leptin gene expression. 
 
Aim To compare glucose metabolism and mRNA expression of the Fto, leptin and 
other appetite-regulating genes in hypothalamic, adipose and/or other tissues of 
offspring of female mice fed high vs. low GI starch diets throughout pregnancy. 
Female C57BL/6 mice were randomly assigned to a low GI, high GI diet, or 
standard chow from 4 weeks of age and then mated with males who were fed the 
standard chow. In Study 1, male pups (n = 40) were weaned at the end of postnatal 
week 4 and divided into 2 subgroups, one following the chow diet and one their 
mother’s diet until 20 weeks of age (i.e. early life and life-long exposure 
respectively). At postnatal week 18, glucose tolerance and insulin sensitivity were 
determined. At week 20, the pups were sacrificed for tissue collection (hypothalamus, 
brown adipose tissue, liver, visceral and subcutaneous fat, red muscle and white 
muscle). Tissues were analysed for gene expression and histological findings. In 
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Study 2, female mice were sacrificed at gestation day 16-18 and placentas recovered. 
Gene expression was measured by quantitative real-time PCR. 
 
Results Fto gene expression in the hypothalamus of offspring fed high GI 
starch from conception to postnatal week 20 was 2.5-fold higher than those fed low 
GI starch for the same time period (p = 0.01). Similarly, placental Fto gene 
expression was 3.8-fold higher in mothers fed the high GI starch diet vs. the low GI 
diet (p = 0.0003). By contrast, both early life and life-long exposure to a high GI diet 
were associated with lower Fto gene expression in white muscle (p = 0.0001). In the 
visceral adipose tissue, leptin gene expression was 3.3-fold higher in offspring 
exposed to the low GI diet from conception to week 20 and 4.4-fold higher in the 
offspring exposed to the low GI diet in early life. Plasma levels of the ‘hunger’ 
hormone ghrelin were significantly lower in offspring who received the low GI diet 
throughout life (202.0 ± 49.5 vs. 81.3 ± 21.6 pg/mL in high vs. low GI respectively, 
p = 0.02), while levels of the ‘satiety’ hormone leptin were higher (0.62 ± 0.18 vs. 
3.88 ± 1.4 respectively, p = 0.001). The co-expression of hypothalamic appetite 
genes AGRP/NPY and POMC/CART was also differentially regulated by the nature 
of the dietary carbohydrates.  In this study, differences in diet, gene expression and 
hormone levels were not accompanied by differences in phenotype, including body 
weight, glucose tolerance or insulin sensitivity. Similarly, despite interesting trends, 
the histological findings did not show a definitive effect of the maternal diet on 
offspring liver tissue morphology. Offspring who were weaned to chow at week 5 
demonstrated similar trends to those fed high vs. low GI diets throughout life.  
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Conclusion  This study suggests that carbohydrate quality, specifically the GI 
and/or rate of starch digestion in maternal diets, can differentially regulate the 
expression of the Fto and leptin gene in offspring tissues even in the absence of 
phenotypic differences. Furthermore, the nature of the dietary carbohydrates can 
regulate the well recognised co-expression of AGRP/NPY and POMC/CART in the 
hypothalamus. The findings imply that epigenetic changes induced in early life 
underlie observed differences in fat mass and insulin resistance in previous studies of 
high vs. low GI feeding. It is therefore possible that changes in the nature of the 
carbohydrate in human diets may explain in part the current epidemic of obesity in 
children and adults. Dietary interventions during pregnancy that reduce the rate of 
digestion of carbohydrate and postprandial glycaemia deserve further research. 
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Chapter 1  Introduction 
 
1.1 Obesity 
The past two decades have been indelibly marked by an epidemic of obesity. The 
World Health Organisation (WHO) identifies obesity as the fifth leading cause of 
death and a major contributor to the burden of type 2 diabetes, ischaemic heart 
disease and certain cancers. The physiological, psychological and economic costs 
span all cultural and ethnic backgrounds (1). Financial costs begin to increase at a 
body mass index (BMI) ≥25 kg/m2 and include both direct (medical and non-medical) 
and indirect expenses (2). Indeed, indirect costs such as decreases in workforce 
productivity and premature mortality are often higher than direct costs. In the USA 
in 2008, the medical costs alone were estimated to be USD147 billion (3). 
 
In Australia, the most recent population-based data are derived from the Australian 
Diabetes, Obesity and Lifestyle (AusDiab) study (4-6) conducted in 1999-2000, with 
a 5-year follow-up study in 2005, and a 12-year follow-up in 2012. The prevalence 
of obesity in the adults was reported to be 27% in 2011-2012 and projected to reach 
34% by 2025. In 2010, average annual direct and indirect costs to the Australian 
government were estimated to be AUD56 billion (4).  
 
The burden of obesity is not limited to its economic impact. It also has a significant 
social impact because obese individuals have a lower quality of life and more 
functional limitations (2, 7, 8). Clinical depression and a range of other psychosocial 
disturbances are common, yet substantial weight loss brings about a marked 
improvement in psychological comorbidity (9). The impact on quality of life remains 
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even after adjusting for demographics, health habits, medical conditions (9). Sturm 
(10) summarised it in this way: “obesity has a greater negative impact on quality of 
life than 20 years of aging”. 
 
Obesity and its metabolic sequalae are not a modern phenomenon. Over 2400 years 
ago in ancient Greece, Hippocrates stated that “sudden death is more common in 
those who are naturally fat than in the lean” (11). He also wrote “corpulence is not 
only a disease itself, but the harbinger of others”. Even today, most clinicians do not 
recognise obesity as a disease in itself. It was not until 1660 that the word “obesity” 
was first used although the condition was relatively uncommon (12). Three hundred 
years later, however, obesity became an epidemic afflicting most high-income 
countries, followed soon after by many middle- and low-income countries. In 2008, 
a total of 1.46 billion adults worldwide were classified as overweight (BMI >25 
kg/m²) and 502 million as obese (BMI >30 kg/m²). At the same time, around 170 
million children (aged <18 years) globally were classiﬁed as overweight or obese, 
double that of earlier estimates (13).   
 
In 2012 WHO estimated that 2.8 million people worldwide died every year due to 
obesity and its complications (14). Clearly socio-political shifts have contributed to 
the rise. From wars and famine in the first half of the 20
th
 century, many nations 
underwent a transformation in the second half that included a microbiologically safe, 
abundant, cheap and palatable food supply. Many researchers have identified the 
onset of global obesity with the availability of energy dense fast-foods coupled with 
the adoption of a sedentary lifestyle. However, others believe that the origins of 
obesity are far more complex (15). 
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In the last decade, research around obesity has focused on the interplay between 
individuals and their environmental influences (lifestyle and nutrition) as well as 
potential genetic determinants (16). Health professionals acknowledge that weight 
loss is a constant challenge and unlikely to be sustained over the long term. The 
paradigm has therefore shifted and prevention of weight gain has become the goal 
for health practitioners and researchers globally (17). 
 
Most studies of long-term weight gain have evaluated current behaviours that could 
be targeted for change over time. The scientific world has proposed several strategies 
to prevent obesity and reduce the risk of development of metabolic syndrome and 
associated disorders (18). These include lifestyle aspects such as increased physical 
activity and a healthy diet. The recommended dietary pattern proposes that 
carbohydrates (mainly complex carbohydrates) should contribute to around 50% of 
the total daily calorie intake, healthy fats to around 30% of the total daily calorie 
intake and an increased consumption of fruits and vegetables (19). Clearly there is no 
one single solution to the problem of obesity. Simple advice such as balancing the 
calories consumed and those expended e.g. “eat less and exercise more” is rarely 
effective.  
 
In 2011, Mozaffarian et al. conducted a prospective investigation of three separate 
cohorts involving ~120,000 non-obese individuals, free of chronic diseases, that 
were followed up over several years (17). As expected, several lifestyle choices were 
independently associated with long-term weight gain, including consumption of 
specific foods and beverages, physical activity, alcohol use, television watching and 
smoking. It also showed that on average weight gain in non-obese populations is 
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very gradual. Nonetheless, this accumulated weight over time had serious health 
implications including metabolic dysfunction, type 2 diabetes, cardiovascular disease 
and cancer. 
 
The most important finding, however, was that the magnitude of weight gain varied 
for specific foods and beverages. Per serving they found that potatoes, refined grains 
and other processed foods were associated with the greatest weight gain per unit of 
time, while increased consumption of vegetables, nuts, fruits, and whole grains were 
associated with weight loss. The authors suggest that consumption of higher fibre 
foods slows digestion and increases satiety, resulting in a reduced intake of highly 
caloric processed foods and lower caloric intake in general. Interestingly, several 
dietary metrics that are currently emphasized (such as fat content, energy density, 
and added sugars), did not reliably identify the dietary factors that were found to be 
associated with long-term weight gain. For example, most of the foods that were 
positively associated with weight gain were starches or refined carbohydrates. This is 
not the first study suggesting that carbohydrate quality could be more critical than 
what we have thought to date. 
 
In 1994, Brand-Miller and Colagiuri published the Carnivore Connection hypothesis 
(a revised edition was published in 2012) (20). This hypothesis argues that during 
human evolution we experienced over several dietary patterns; from diets with 
mostly plants in early hominids to those with a high animal:plant ratio and scarcity 
of dietary carbohydrate, and then more recently to high-carbohydrate, high-
glycaemic index carbohydrates that characterise modern diets. These dietary changes 
are likely to have precipitated metabolic adaptations, particularly in relation to 
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glucose metabolism and insulin sensitivity. Carbohydrate quality changed markedly 
during the industrial revolution in the period 1760-1840 and again with 
developments in food processing (e.g. extrusion technology) (21). New high-speed 
steel roller mills produced finely ground cereal flours, removing the fibre and 
resulting in increased starch gelatinization during cooking. Prior to that, cereals were 
consumed whole or coarsely ground or flaked, with the endosperm and fibre intact 
(20). With this modern high carbohydrate dietary pattern, the digestion and 
absorption of the carbohydrates changed radically. Changes were less dramatic for 
meat, fruit and vegetables since we still consume these in much the same form.  
 
Many researchers have noted that the recommended reduction of calories from fat 
has resulted in a compensatory increased consumption of refined, high GI 
carbohydrates (bread, rolls, pizza, white rice, ready-to-eat cold cereals) and added 
sugars (22, 23). Indeed, some argue persuasively that refined carbohydrates are a 
greater cause of metabolic disturbance than saturated fat and sedentary lifestyle (24). 
Nevertheless, a low-fat, high-carbohydrate diet still remains the most common 
dietary recommendation, although carbohydrate quality is now stressed and 
minimally processed foods such as whole grains, legumes, and vegetables are 
favoured.  
 
The National Institutes of Health USA currently spends nearly $800 million a year 
on research designed to unravel and understand the metabolic, genetic and 
neurological foundations of obesity. Unfortunately, despite this expenditure, real 
progress is not being made and the prevalence of obesity continues to climb (13). 
New approaches are therefore needed. One approach is the science of epigenetics.  
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In deciding and designing the direction of my PhD research, I focused on the 
connections that interested me most. In the following paragraphs, my aim is to set 
the scene for the research decisions I was led to take based on my interpretation of 
the scientific evidence that was available to me. A schematic representation of the 
train of thought that initiated this research is indicated in Figure 1 below: 
 
 
 
 
Figure 1. Schematic representation of the interplay between factors influencing 
the risk of obesity and their impact on later susceptibility to disease. (PA = 
physical activity, NCD = non communicable diseases, CVD = cardiovascular 
disease). 
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1.2 Genes and obesity 
Every year, scientific conferences bring together the latest updates and possible 
treatments for obesity. In the strictly medical field, surgery and drugs are often the 
focus (13). But the data on the use of the existing drugs to treat obesity are not 
promising (25). Sibutramine and orlistat have serious side effects making their use as 
obesity solution agents problematic. The possibility to identify genetic targets that 
could offer a valuable solution and better understanding of how BMI is determined, 
has become a very promising and exciting field.  
 
In 1962, geneticist James V. Neel, published the "Thrifty Genotype" hypothesis in 
his paper "Diabetes Mellitus: A 'Thrifty' Genotype Rendered Detrimental by 
'Progress'?” (26). He proposed that there has been a natural adaptation selective 
process during our hunter-gatherer evolutionary existence with periods of feast and 
famine that have created natural selection of thrifty genes, i.e. genes that “save” and 
store energy. These adaptations now predispose people to chronic diseases of the 
modern civilization such as obesity and type 2 diabetes. According to Neel, the 
genes encode for proteins that are involved in maintaining energy balance and 
important metabolic functions such as fat oxidation. Based on this hypothesis, the 
thrifty gene variants, born as an evolutionary advantage, became a disadvantage in 
the modern obesogenic society.  
 
A large number of studies, some of them using monozygotic and dizygotic twins to 
observe closely the interaction between gene and environment, have supported the 
hypothesis (27). Yet, the hypothesis still remains controversial and often criticized as 
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there are arguments that the time periods and the length of the famines were not 
enough to justify a natural selection (28). 
 
In 2008, biologist John Speakman presented an alternative explanation, referred to as 
the ‘‘drifty hypothesis’’, suggesting that adiposity could be the result of random 
mutations and genetic drift as a result of the interaction with the environment (28, 
29). According to Speakman, periods of food insecurity have been common, 
occurring about once every decade. Nevertheless, since those periods were not 
marked with significant mortality, they become unimportant for genetic natural 
selection. Instead, Speakman suggests that what occurred was a series of random 
allelic mutations with frequencies that also randomly drift. He called them the ‘drifty 
genes’, and he argues that the “genetic lottery” can predispose to obesity and other 
modern metabolic disorders. As George Bray, a leading obesity researcher says, “the 
genetic background loads the gun, but the environment pulls the trigger” (30). 
 
Genome-wide association studies and further investigations on the gene-environment 
interactions are increasingly promising (31). There are at least 37 known single 
nucleotide polymorphisms (SNPs) that are associated with obesity (31) and gene–
environment and gene–behaviour interactions, including interactions in the 
intrauterine environment that require further study. The new field of epigenetics 
focuses on the study of heritable changes in gene expression that are not due to 
changes in DNA sequence, but to other chromosomal changes that occur as a result 
of environmental influences (32-34). Epigenetic mechanisms that modify the 
expression of genes and contribute to obesity must be investigated with valid 
methodologies that minimise the number of environmental variables (13). 
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A recent review (35) summarised advances in obesity genetics, describing promising 
research that may make personalized obesity therapy a near reality. Monogenic 
obesity resulting from a single gene or chromosomal region mutation is rare, yet this 
form of obesity has allowed us to investigate and better comprehend the 
neuroendocrine factors that are implicated in the development of obesity. An 
important single gene mutation that opened the door on this direction, was that 
observed in the leptin gene in the ob/ob mouse strain that led to the discovery of the 
leptin–melanocortin signalling pathway and its putative role in energy homeostasis 
and body weight regulation. Since then, several genes involved in this pathway have 
become targets of interest, stimulating research on protein products such as the 
prohormone pro-opiomelanocortin (POMC) and melanocortin 4 receptor (MC4R) 
(36).  
 
Polygenic obesity, referred to as ‘common obesity’, is believed to be the result of the 
combined effect of genetic variants and SNPs in multiple genes (37). These variants 
and their interaction with environmental risk factors have become a promising field 
for research. Linkage analysis and genome wide association studies looking for 
association of genes with type 2 diabetes and obesity, have indicated and 
subsequently confirmed through replication, several genes that seem to be 
significantly associated with an increased body mass index (BMI) and adiposity (38).  
 
The most compelling evidence came from a gene expressed mainly in the 
hypothalamus, located on chromosome 16q12.2 region, referred to as the fat mass 
and obesity-associated FTO gene (39-41). After its first discovery, it was found that 
FTO belongs to the superfamily of Fe(II) 2-oxoglutarate (2-OG)-dependent 
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dioxygenases and encodes a 2-oxoglutarate–dependent nucleic acid demethylase (42, 
43). The amino acid sequence of the transcribed FTO protein showed high similarity 
with the enzyme AlkB which oxidatively demethylates DNA. The researchers of 
these discoveries discussed the possibility that the catalytic activity of FTO may 
regulate the transcription of genes involved in metabolism by nucleic acid 
demethylation or it may act as a nucleic acid repair enzyme. Evidence suggests that a 
breakdown of genomic repair processes leads to obesity and metabolic syndrome 
(44). Furthermore, in vitro, FTO demethylates m6A-containing RNA which implies 
that the FTO gene is involved in reversible chemical modification of RNA (45, 46). 
 
Numerous studies since have shown an association with obesity traits (47, 48) of 
various SNPs in this gene, all presenting within a 47-kilobase block including parts 
of the first two introns and exon 2 of FTO (49). A table summarising the associations 
between the variants of the fto gene and obesity traits is shown in Appendix 1. But it 
was one particular variant that maintained its association with BMI and type 2 
diabetes, even after data from several separate cohorts were adjusted for BMI (41). 
This was rs9939609, a cluster of 10 SNPs in the first intron of FTO. At the time, this 
variant had the strongest association between a gene and obesity risk (50). However, 
most recent developments have indicated that all of the identified FTO SNPs within 
a 47-kilobase (kb) region of high linkage disequilibriumin introns 1 and 2 of FTO 
(each of them with different frequencies in the various populations) belong to the 
same highly correlated cluster. All are associated with BMI and other obesity-related 
traits at similar significance levels (51). Individuals homozygous for risk alleles of 
the associated SNPs weigh approximately 3 kg more than individuals homozygous 
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for non-risk alleles, underscoring the significant phenotypic impact of these common 
variants (52). 
 
FTO is not only statistically the strongest associated gene but also that with the 
largest effect size (53), even though its physiological role and the mechanism of its 
association to increased adiposity and weight need more investigation. The high 
expression of this gene in the hypothalamus, the regulatory centre of energy balance, 
led researchers to believe that FTO may influence adiposity through its impact on 
energy homeostasis (54). 
 
The intronic position of these variants means they do not affect the amino acid 
sequence of the expressed protein. Rather, they affect the regulation or expression of 
the gene or that of a nearby gene or genes (55) and it can be tissue specific (or not). 
All these possibilities are now being explored in modern research.  
 
In the early stages after the discovery of the FTO gene, a study showed that the 
expression of FTO in the hypothalamus was regulated by feeding and fasting (56), 
suggesting a role in the control of energy homeostasis. Indeed FTO was significantly 
up-regulated (+~40%) in the hypothalamus of rats after 48 hour food deprivation. 
Two similar studies conducted in mice showed the reverse outcome; Fto mRNA 
transcription levels in the brain of fasted mice were reduced. Nevertheless, these 
associations point towards a connection between this gene and obesity through 
mechanisms of feeding and fasting (42, 57). When considering these outcomes, the 
researchers looked at other genes associated with monogenic severe obesity, which 
appeared to be regulated by diet. For example, brain derived neurotrophic factor 
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(BDNF) expression has been shown to be altered by consumption of high fat diet (58, 
59). This encouraged them to further explore the possibility that FTO was 
nutritionally regulated (55). 
 
1.2.1 Human studies on the association of obesity and the FTO gene 
In 2009, a cross-sectional analysis suggested that consuming a high-fat diet 
accentuated susceptibility to obesity by the FTO variant (60). However, in 2011 the 
same researchers examined the association between fat intake and mortality as a 
function of FTO genotype. Their results were inconclusive because although the 
FTO genotype was associated with both fat mass and lean mass, the level of fat 
intake modified only the association with fat mass (61). Of course, as cross-sectional 
studies, they do not investigate directly the effect of diet or more specifically of the 
type of dietary fat on FTO gene. Furthermore, it has been shown very difficult to 
obtain accurate data on fat intake in human studies. 
 
Two large studies, the GOLDN and the BPRHS studies, have explored the 
association between fat and carbohydrate intake and FTO gene variation with BMI 
(62). Interestingly, participants with two copies of the FTO risk allele had a higher 
mean BMI compared to the other genotypes only when they had high saturated fat 
intake. There were no significant associations with total carbohydrate intake. 
 
The Diabetes Prevention Program (DPP) study was a US randomised controlled trial 
in which 27 centres participated with over 3,500 high risk participants randomised to 
either a pharmaceutical intervention, intensive lifestyle modification (including a 
significant weight loss by eating less fat and fewer calories) or placebo, to prevent 
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the development of type 2 diabetes. The baseline and one year results were analysed 
to look for associations between the outcomes and the FTO gene variant rs9939609 
(63). The study showed that at baseline the high risk A allele was associated with 
greater weight and BMI, but not adiposity or the change at one year in any 
anthropometric trait. Their data were adjusted for age, sex and ethnicity. They also 
examined the possible influence of the genotype on the effects of the various 
treatments at one year. It appeared that the risk A allele was associated with a greater 
increase in subcutaneous adipose tissue in the placebo group, but not the others. A 
limitation of this study, as in all human studies, is that the nutritional 
recommendations the individuals were given were generalised (lowering fat intake, 
in particular saturated fat) and lacked precision. 
 
Similarly, in the Finnish Diabetes Prevention study (64), researchers investigated 
whether the FTO gene variant was associated with body weight and BMI and long-
term weight changes. Approximately 500 participants with impaired glucose 
tolerance were randomized to control and lifestyle intervention groups. At baseline, 
the high risk homozygous FTO genotype female carriers had higher BMI than 
subjects with other genotypes and this was maintained throughout the four years of 
follow-up. This association was not observed in men. The FTO genotype did not 
appear to have any influence on weight reduction in either of the groups. Again here, 
the advice for the intervention group was to reduce saturated fat intake (use low-fat 
dairy and meat products and margarines or vegetable oils rich in monounsaturated 
fatty acids). It was also recommended to consume more than 50% of daily calories 
from carbohydrates. In 2012, after further data analysis in this study, an update was 
published indicating that at baseline and during the follow-up, the association 
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between FTO and BMI was more pronounced in those having a diet high in fat and 
low in carbohydrates and fibre. However, a limitation of the Finnish study was that 
the statistical power was low because it involved only ~500 participants. 
Nevertheless, the study was further confirmation of a link between the dietary factors, 
FTO genotypes and obesity. 
 
Several human studies have indicated that a possible mechanism of association 
between FTO and obesity is through an effect on energy intake and not energy 
expenditure (65-69). In one of the latest studies, Wardel and colleagues (66) assessed 
the data from a population based twin cohort of more than 3000 children in the 
United Kingdom that measured habitual appetitive behaviour. In agreement with 
previous studies, they confirmed that one copy of the A allele (in rs9939609) 
increased body weight by 1.5 kg in adults and children. They also showed a strong 
association with higher waist circumference. But a unique finding from this research 
group was that the carriers of two copies of the A risk allele had significantly lower 
satiety responsiveness compared to the other genotypes, even after controlling for 
BMI. The researchers suggested that FTO may have a direct effect on appetite and 
this could be the mechanism that in turn influences adiposity. This theory is also 
supported by a study in 2009, in which 16.5% more children with at least one risk A 
allele reported loss of control eating, compared to the low risk allele T children. In 
this study, children with the risk allele also consumed more calories from fat than 
those with the low risk allele (70). Thus, the above findings together with the fact 
that the FTO gene is mainly expressed in the hypothalamus suggest this gene plays a 
role in the control of satiety or appetite (71). 
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A new hypothesis was tested by Sovio and colleagues in 2011 (72), in relation to an 
age-dependent association between the FTO gene and BMI in children. They 
conducted a meta-analysis of eight cohort studies, looking at data derived from early 
infancy to 13 years of age. They also observed the timing of BMI adiposity rebound 
(AR), which is inversely related to the risk of later obesity and used as a marker of 
an advanced BMI-for-age. The FTO risk allele was associated with a higher BMI 
from the age of five years onwards, though the opposite was observed before the age 
of two and a half years. This suggested that the effect of this gene followed a shift in 
the age scale leading simultaneously to lower BMI during infancy and higher BMI in 
childhood, indicating an association with the timing of AR and its metabolic 
consequences (risk of increased adult BMI and type 2 diabetes). Similarly, a review 
of the data collected during the Fels longitudinal study indicated there was no 
association between the FTO gene and growth status or velocity until the age of three 
(73). 
 
Meanwhile in Spain, a research group was analysing data derived from the placentas 
of women that took part in a birth cohort study (74). They were investigating an 
association between FTO gene expression in the placenta and fetal growth, weight 
gain and length. Placental FTO expression was positively associated with fetal 
weight and length but also with increased fetal-to-placental weight ratio. 
Nevertheless, there was no difference in the placental FTO expression levels among 
the babies with the various genotypes for the rs9939609 SNP (AA, AT, TT). 
 
Finally, as part of a larger multicentre international study “HELENA” designed to 
investigate the interactions between environmental influences and cardiovascular 
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disease, an analysis was undertaken on the association of the FTO gene and serum 
leptin concentrations in 655 adolescent participants (75). The results indicated the 
high risk A allele was positively associated with higher serum leptin levels. The 
association remained after all data were adjusted for adiposity and other confounding 
factors such as physical activity. This suggested the A allele may be linked with 
leptin resistance thus indicating that the mechanism of action may lie in the control 
of energy balance. 
 
In summary, human studies to date indicate that the association between obesity and 
the FTO gene is the result of the effect of the high risk A allele on appetite and 
energy intake, with a reduction in satiety and a positive association with increased 
dietary fat/saturated fat intake (53). 
 
1.2.2 Animal studies on the association of obesity and the FTO gene 
Animal models, and particularly mice models, are a valuable tool in the research of 
human disease due to their physiology, anatomy and genes being very similar. They 
also allow us to research and apply protocols in shorter periods of time and in tightly 
controlled environmental conditions than what is possible with humans. Moreover, 
sophisticated techniques allow us not only to observe wild types, but also to 
genetically engineer animal models that better serve the aims of our research projects 
(76). 
 
In 2008, the expression of the Fto gene was investigated in pre-existing mouse 
models of obesity under different dietary manipulations (fed vs. fasted) (57). The 
data showed Fto gene expression was significantly higher in the hypothalamus 
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compared to other tissues such as adipose, pancreas and liver. In both lean and obese 
mice, Fto expression in the hypothalamus was lower in fasted compared to fed 
animals. Similar outcomes were published in another study (42), where laser-
dissected hypothalamic arcuate nuclei of mice (freely feeding, fasted, and fasted + 
daily injections of leptin) were analysed for differences in Fto expression levels. Fto 
expression in the two fasted groups was 60% lower compared with the fed group. 
Although these results varied from those in fed vs. fasted rats (56), the scientific 
world proposed two likely causes for the discrepancy; firstly the difference between 
these two animals in their sensitivity to starvation and secondly the diverse 
methodological protocols that could impact on Fto gene expression (77). Despite the 
inconsistency, the results indicated that Fto mRNA expression could be regulated by 
nutrition. 
 
In 2009, the first specifically produced animal model to study the Fto gene and its 
putative role in energy homeostasis was created by Fisher and colleagues (78). It was 
a knockout mice generated by replacing exons 2 and 3. An important outcome during 
the generation of this mutant animal model was that the knockout mice were 
produced according to the Mendelian ratio. So, the authors suggested that Fto is not 
essential for embryonic development (78). Their data showed that Fto knockout mice 
had significantly less adiposity and lean body mass indicative of postnatal growth 
retardation. Additionally, these mice had an elevated metabolic rate, a result that at 
that time contrasted with the outcomes of the published human studies (79). The 
findings of this study were strongly criticized on the grounds it was under-powered 
and had several issues in regards to the measurement and calculation of energy 
expenditure. 
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To obtain a better understanding of the functional role of the Fto protein product, 
Gao and colleagues (80) produced two mouse models: one with a full body deletion 
of the Fto gene and the second with a conditional deletion of the Fto gene only in the 
nervous system. They observed that the whole body deletion of the Fto gene was 
associated with postnatal growth retardation and confirmed the outcomes published 
by Fisher and colleagues (78). An important contribution of this study was that mice 
with the conditional deletion in the nervous system were phenotypically similar to 
the full body knockout mice thus presenting similar postnatal growth retardation. 
This was interpreted as a strong indication that Fto gene protein acts in the brain to 
regulate growth. A puzzling finding of this study compared to human studies at the 
time was that both knockout models did not show any association with either the 
chow or the high fat diet to which they were exposed.  
 
Meanwhile, a study conducted in Göttingen minipigs (81) indicated that after 11 
weeks of either chow or high cholesterol feeding, Fto gene expression in the brain 
cortex was higher in the cholesterol-fed minipigs compared to the controls. Another 
study published the same year, was conducted on sheep (82), aiming to shed light 
into the interaction between the in utero environment and the regulation of the FTO 
gene. Pregnant animals were either fed to meet 100% of their energy requirements or 
were nutrient restricted by 50%. The study showed that prenatal nutrient restriction 
did not alter Fto gene expression in the hypothalamus of the newborn. But when 
these lambs of nutrient restricted mothers were exposed for one year to an 
obesogenic environment, Fto gene expression in the hypothalamus was up-regulated.  
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Church et al. (83) engineered three new mice models that globally expressed one, 
two or three additional copies of the Fto gene. They conducted a study to compare 
the effects of these additional gene copies in relation to obesity in mice that were fed 
standard chow diet and high fat diet. They showed that there was a dose-dependent 
increase in weight and fat mass with the different Fto over-expression models both in 
the chow and the high fat-fed mice. Also, there was a positive increase in food intake 
relative to the level of Fto over-expression. This again was observed in both diet 
groups. Finally, they also reported that mice with three additional copies of the Fto 
gene fed a high fat diet were glucose intolerant. These outcomes opened new 
perspectives in the research around this gene, as they suggested that systematic 
overexpression of FTO was associated with obesity (i.e. higher food intake and 
possibly glucose intolerance) and therefore the search for a therapeutic mechanism 
that acts on this gene became a research target. 
 
The same research group that had previously used mice (42), conducted a new study 
to investigate the effects of high fat feeding on Fto expression in rats (84). They 
demonstrated that expression was 2.5 fold higher in the arcuate nuclei of the high 
fat-fed vs. chow-fed rats. Interestingly, in this study the reduction in Fto expression 
in the arcuate nuclei of the chow-fed rats was associated with an increased food 
intake. This finding was consistent with their previous observation in the arcuate 
nuclei of mice (42) and suggest a possible effect of Fto on appetite. 
 
Finally, a recent study on mice hypothalamic cell cultures (85) indicated that 12 
hours of glucose deprivation down-regulated Fto mRNA expression by 50%, 
whereas just 6 hours of amino acid deprivation resulted in 60% reduction in Fto 
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transcript levels. This suggests that FTO expression is altered by the availability of 
both amino acids and glucose. Taken together, these findings suggest that both the 
quantity and quality of nutrients available to the body alter the regulation of the FTO 
gene in the appetite-specific areas of the brain. It is therefore conceivable that 
specific nutritional interventions may counteract the effects of the high risk genotype 
of the FTO gene. 
 
1.3 The relationship between the Developmental Origins of Health 
and Disease hypothesis and nutritional regulation of gene expression  
1.3.1 The Developmental Origins of Health and Disease (DOHAD) 
There has been much debate in the last 20 years in regards to the developmental 
origins of adult disease hypothesis, originally formulated by Dr David Barker (86-
88). It postulated that environmental factors, particularly maternal nutrition, act in 
early life to programme the risks for adverse health outcomes, such as cardiovascular 
disease, obesity and the metabolic syndrome in adult life (89, 90). The hypothesis 
initiated a new field of research,  known today as the Developmental Origins of 
Health and Disease (DOHAD) (91). This branch of research investigates how 
environmental factors, particularly nutritional insults, during the phase of 
developmental plasticity in the womb, impact structures of organs in the fetus and 
interact with genotypic variation, leading to chronic disease in adult life (i.e. 
metabolic syndrome, type 2 diabetes, etc.).  
 
Recent research provides compelling evidence in support of the DOHAD hypothesis 
(92). Developmental plasticity in utero gives rise to phenotypes better suited to that 
specific environment (88, 93) and maternal nutrition has the potential to impact fetal 
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growth and lead to disease in later life (92), particularly where the environment 
differs from the one in which the fetus grew. This assumption of “programming”, the 
ability to change structures, functions and responses in the new animal, is the central 
concept of this theory (94). These changes, not necessarily evident at birth (94), have 
been ascribed to epigenetic modifications of the gene that alter expression but 
convey no alteration of the DNA sequence (95). The epigenome is most vulnerable 
to environmental factors during the periconceptional and intrauterine period,  thereby 
increasing the risk of adult disease more so than later exposure (96). 
 
Nutrient imbalance in fetal life has been shown to be associated with higher risk of 
hypertension, type 2 diabetes and obesity in later life even when no changes in fetal 
growth rates are observed (97). The proposed epigenetic mechanisms elicited by 
nutritional factors include DNA methylation, histone modification and non-coding 
microRNAs (98, 99). Table 1.1 (below) summarises data from two reviews (98, 99) 
and highlights important research demonstrating the role of these mechanisms in 
physiological and clinical outcomes. 
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Table 1.1 Examples of the association of nutritional factors and metabolic 
effects through epigenetic mechanisms. Table adapted from Canani et al. (98) and 
Milagro et al. (99). 
Epigenetic 
mechanisms 
Nutritional factors Metabolic effects 
DNA 
methylation 
Vitamin B12 Insulin resistance, obesity 
Folate Adiposity, Insulin resistance 
Eicosapentaenoic acid n-3 Polyunsaturated fatty acid metabolism 
Docosahexaenoic acid n-3 Polyunsaturated fatty acid metabolism 
Arachidonic acid n-6 Polyunsaturated fatty acid metabolism 
Ascorbate Antioxidant processes 
Genistein Body weight 
Soy isoflavones Body weight, insulin sensitivity 
Low protein diet Impact on the amino acid response pathway 
and cholesterol metabolism 
High fat diet Impact on leptin gene in adipose tissue and 
melanocortin receptor 4 in brain  
Hyper-caloric diets Impact on the expression of genes involved in 
the control of appetite and energy metabolism 
High fat diet and dietary 
protein restriction 
Obesity, metabolic syndrome and impaired 
glucose metabolism 
Calorie restriction Increased adrenal mass and cortisol response 
to stress 
miRNA Curcumin Inflammation response, body weight 
Soya, retinoic acid Cancer prevention and therapy 
High cholesterol diet Obesity 
Dietary methyl 
deficiency 
Non-alcoholic steatohepatitis and liver cancer 
Histone 
modifications 
Retinol Antioxidant processes 
Tocopherols Antioxidant processes 
Resveratrol Body weight, liver steatosis 
Sulforaphane Adipocyte differentiation 
Dietary protein 
restriction 
Type 2 diabetes 
High fat diet / calorie 
restriction 
increased histone 4 acetylation in adipose 
tissue 
Histone and 
DNA 
methylation 
Epigallocatechin 3-
gallate 
Weight reduction, insulin sensitivity, liver 
steatosis 
Choline Liver steatosis 
Betaine Liver steatosis, insulin resistance 
Methionine Insulin resistance, obesity 
Serine, Glycine, 
Histidine 
Amino acid metabolism 
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1.3.2 Possible epigenetic mechanisms 
There is now a large body of evidence based on both human and animal research on 
the association of prenatal nutritional exposure and the risk of adult obesity and 
metabolic disorders (92, 97, 99, 100). Nonetheless, the support coming from human 
population studies has been limited (97) and does not prove a cause-effect 
relationship. The advantage of animal experiments is they allow observations of how 
specific modifications to the diet of the mother can produce permanent effects in the 
metabolism of the fetus (101). Indeed, the most recent studies in rodents have 
demonstrated that the central nervous system, part of which is the hypothalamic 
energy homeostasis circuit, develops in utero and continues to mature in the suckling 
period (102, 103). Different nutritional exposures and modifications during this 
critical developmental period have led to outcomes in support of the early origins 
hypothesis. Indeed, Coan et al. (104) were able to show that even subtle variations in 
dietary composition of the maternal diet lead to functional adaptations in placental 
phenotype that optimise nutrient transfer to the fetus and regulate fetal growth. 
 
One of the nutritional factors known to have a significant epigenetic effect linked 
with obesity is glucose (99, 105). Maternal blood glucose crosses the placenta into 
the fetal circulation and can directly influence the epigenetic profile (106). Using 
ultrasound fetal measurements, Farah et al. showed that maternal glycaemia 
influenced birth weight, fetal adiposity and distribution of adipose tissue in women 
without diagnosed gestational diabetes mellitus (GDM) (107). The Hyperglycaemia 
and Adverse Pregnancy Outcomes (HAPO) study confirmed that maternal glucose 
levels below those diagnostic of diabetes were associated with increased birth weight 
and cord-blood serum C-peptide levels (a measure of fetal insulin secretion) 
- 40 - 
 
Bouchard et al. (106) demonstrated that higher glucose concentrations during the 
second trimester of pregnancy were associated with lower placental adiponectin 
DNA methylation. Lower methylation levels were also associated with higher insulin 
resistance during the last two trimesters of pregnancy. Because adiponectin is 
suspected to have insulin-sensitizing properties, these epigenetic adaptations have 
the potential to induce changes in glucose metabolism in the mother and offspring. 
Finally, Deierlein et al. found that higher maternal glucose concentrations were 
proportionally associated with higher BMI in offspring at 3 years of age (108). These 
findings together strengthen the evidence that maternal glucose plays an important 
role in intrauterine fetal programming.  
 
GDM offers an almost perfect example for researchers to better investigate the 
connections between maternal glucose levels and epigenetic effects during gestation.  
Maternal diabetes in pregnancy is strongly associated with an increased rate of 
offspring childhood obesity, impaired glucose tolerance, and type 2 diabetes later in 
life (109). It was indeed these observations in GDM that prompted the first 
investigations on the impact of in utero conditions on the risk of developing chronic 
diseases and gave grounds to the early origins of adult disease theory (110). The 
most plausible mechanism is believed to be the increased glucose transfer to the 
fetus caused by the maternal hyperglycaemia which leads to an increased fetal 
insulin secretion. Fetal hyperinsulinaemia occurs during the critical time window of 
brain development when the hypothalamic regulation centre (and thus metabolism 
and energy regulation systems) are being laid down (111, 112). A study on the 
placentas of GDM-affected mothers found functional modifications at the leptin and 
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adiponectin genes that influenced the regulation of energy metabolism in the 
offspring, leading to obesity (110).  
 
These effects of maternal hyperglycemica are further supported by recent animal 
work that demonstrates that metabolic memory (the phenomenon where diabetes 
complications persist and progress after glycaemic recovery is achieved) is heritable 
and its transmission correlates with hyperglycaemia-induced DNA hypomethylation 
and altered gene expression (113). This study used a zebrafish model in which the 
daughter tissue, which was not exposed to hyperglycaemia but was derived from 
tissue that was, showed the same associations. 
 
Mühlhäusler and her group conducted several studies in sheep investigating the 
development of the hypothalamic appetite regulatory neural network in the fetus and 
the effects of intra-fetal glucose infusion during late gestation (114, 115). They 
found that components of the central neural network that regulate appetite and 
energy balance in the adult sheep are expressed already in the developing fetal brain 
and have the potential to operate immediately post-partum (114). When they 
conducted continuous intravenous infusion of glucose in the fetuses of sheep from 
130-140 days of gestation (115), they found that it significantly increased the 
expression of POMC in the arcuate nucleus of the fetal sheep hypothalamus, despite 
the fact that glucose infusion did not increase circulating concentrations of leptin. 
Further studies in sheep have shown that maternal overnutrition increases 
hypothalamic expression of the appetite inhibitor proopiomelanocortin, PPARγ and 
LPL expression in the adipose tissue of the postnatal lamb, as well as leptin mRNA 
expression in perirenal adipose tissue in the fetal sheep in late gestation (116-119). 
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Finally, Mohmaad et al. (102) conducted a rodent study to investigate the possible 
epigenetic modifications associated with the Npy and Pomc genes induced by a high 
carbohydrate diet in the developmental period. In an earlier study, the same research 
group had shown that rearing of newborn rats on a high-carbohydrate milk formula 
resulted in hyperinsulinaemia, which persisted in the post-weaning period and led to 
adult-onset obesity. In the second study, the high carbohydrate milk formula 
administered to neonatal female rats resulted in altered epigenetic regulation of the 
genes involved in the hypothalamic energy homeostatic mechanism. This suggested 
that the changes could contribute to the development of obesity in the adult rat. 
Together, these findings stimulated my interest in investigating the high and low end 
of normal maternal glucose exposure and its programming effects during the in-utero 
and early post weaning period. 
   
1.4 The glycaemic index of foods, its clinical applications and 
outcomes 
Carbohydrates present in different foods have distinct physiological effects, 
including those on postprandial glycaemia and insulinaemia, which can influence the 
rate of digestion, appetite (hunger and satiety), fuel partitioning and metabolic rate. 
The type and quality of carbohydrate foods in human diets has been found to have a 
major impact on health outcomes (120). The glycaemic index (GI) is a food 
classification based on the postprandial blood glucose response relative to a 
reference food, gram for gram of carbohydrate (121). The glycaemic load (GL), the 
mathematical product of the GI and the amount of carbohydrate, encapsulates both 
the quality (i.e. GI) and quantity of carbohydrate, and is the single best predictor of 
postprandial glycaemia (122). In overweight and insulin resistant individuals 
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consuming high GI/GL diets, glycaemic spikes and insulin demand are excessively 
increased. Foods can be classified as low GI (GI <55), medium GI (GI 55-69) or 
high GI (≥70) (123). The given value of a carbohydrate containing food is calculated 
using the average incremental area under the curve (iAUC) of the blood glucose 
levels within a 2 hour period elicited by 50 g of available carbohydrate portion of 
that food, relative to the iAUC elicited by 50 g of pure glucose (124). The GI reflects 
the way the carbohydrates in a given food raise blood glucose levels and the rate it is 
cleared from the bloodstream within this 2 hour period. Slower digestion and 
absorption of carbohydrate elicited by a low GI food results in a more moderate 
increase in the blood sugar levels with a lower peak level when compared to a high 
GI food (123).  
 
Many studies have investigated dietary strategies to limit postprandial 
hyperglycaemia, including high-protein diets, Mediterranean-style diets and low GI 
diets. Compared with conventional healthy diets, diets with a low GI carbohydrate 
composition have shown greater weight loss, metabolic advantages such as improved 
diabetes control, and have been associated with reduced risk of developing type 2 
diabetes, improved satiety, increased utilization of stored fuels and improved weight 
management (20, 125).  
 
Obesity, excess weight, diabetes and pregnancy influence metabolic and endocrine 
pathways and therefore production of hormones and growth factors in different ways 
(125, 126). A recent study investigated whether the GI can impact health in people 
with or without the metabolic syndrome (127). Using a cross-over feeding design 
with a low and a high GI diet in normal and overweight/obese (but otherwise healthy) 
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subjects, they measured biomarkers of inflammation and obesity, including leptin, 
adiponectin, C-reactive protein and IL-6. The low GI diet was associated with 
decreased serum C-reactive protein levels and increased adiponectin concentrations 
in participants with a high body adiposity. Thus, the low GI diet reduced 
inflammation and increased adiponectin (an insulin-sensitising factor) in obese 
people, suggesting that the quality of carbohydrate foods plays a significant role in 
the prevention of obesity-related metabolic dysfunctions. Similarly, a recent meta-
analysis on the possible beneficial effects of long-term low GI diet, indicated that 
pro-inflammatory markers such as CRP were also positively influenced by the diet 
(128). 
 
Evidence shows that pregnant women and those of reproductive age are often at risk 
of obesity or already obese, and therefore have an increased risk of adverse 
pregnancy outcomes (125, 129). However, the priority of a mother’s diet is to ensure 
sufficient supply of nutrients for the fetus to grow. If there is excessive weight gain 
in pregnancy, the complications include gestational diabetes, pre-eclampsia, post-
partum weight retention leading to later obesity, large-for-gestational age (LGA) 
babies and others. Reproductive outcomes have also been correlated with the 
glycaemic load (GL) of the diet, with high GL diets associated with greater risk of 
poor outcomes (125, 130). In the Danish National Birth Cohort (125), birth weight 
increased by 36 g from the lowest to highest GL quintile, with 14% increased risk of 
large for gestational age infants (LGA) in the highest vs. lowest GL quintile. Among 
normal-weight and overweight women, higher rates of gestational weight gain were 
detected in the highest vs. lowest GL quintile. A review of the evidence on the GI of 
the periconceptional, gestational and lactating diet and the metabolic effects on the 
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offspring’s health concluded that a low GI maternal diet can alter maternal blood 
glucose production, insulinaemia and reduce adiposity as well as fetal and placental 
insulin and glucose regulation, fetal growth, birth weight and offspring adiposity 
(131).  
 
Louie et al. published a systematic review article which focused on the evidence 
regarding the effect of dietary GI on maternal and fetal nutrition (132). Taking into 
account the increasing incidence of high birth weight and its association with 
increased risk for obesity in adulthood, the review highlighted the importance of 
strategies to lower maternal blood sugar levels thus avoiding fetal hyperinsulinaemia 
and oxidative stress, both linked to the development of obesity. The human studies 
indicated that a low GI diet can improve pregnancy outcomes in both healthy and 
GDM affected women. This conclusion was also supported in the more recent 
review (133). Indeed, a controversial point of the GI concept has been its cogency 
and power of application in people with various metabolic profiles. The 
reproducibility of GI values and their impact in healthy, hyperinsulinaemic or 
diabetic subjects was tested by Lan-Pidhainy et al. in 2011 (126). They demonstrated 
that the GI values of the defined carbohydrate foods are valid in all subjects 
regardless of their metabolic status.  
 
Danielsen and colleagues recently published the results of an investigation on the 
association between the GI of the maternal diet during pregnancy and the metabolic 
profile in the adult offspring (134). The study was based on the data recovered from 
the Danish Fetal Origin cohort in 1988 and follow-up offspring data in 2008 and 
2009. They were able to show that high dietary GI in pregnancy was significantly 
- 46 - 
 
associated with the metabolic syndrome. An increasing maternal GI diet led to young 
adult offspring presenting higher levels of cholesterol, HOMA-IR, plasma leptin and 
insulin. When the quantity of this type of carbohydrates was increased, there were 
associations with blood pressure and waist circumference as well in the young 
female adults.  
 
The data derived from epidemiological research can therefore be seen to complement 
the findings in animal models. Importantly, animal studies have allowed a more 
controlled identification of the effect of the dietary GI on the metabolic outcomes 
and epigenetic effects that can contribute to later development of disease. 
 
A detailed study conducted in rats indicated that the GI had an independent effect on 
body composition (135). The research was based on multiple experiments and 
showed that rats on a high GI diet, consuming the same amount of food ad libitum 
and gaining the same amount of weight for 7 weeks compared to the low GI group, 
developed hyperinsulinaemia. Also, the high GI-fed rats gained the same weight as 
the low GI group even though consuming less food from week 8 onwards which 
indicated they were metabolically compromised. The authors suggested it could be 
due to lower resting energy expenditure or activity due to decreased lean body mass. 
The study also included an experiment in the obesity-prone C57BL/6J mice. On a 
high GI diet, these mice had lower lean body mass and nearly twice the body fat 
compared to the low GI-fed mice with the same mean body weight.  
Other studies have evaluated the effects of the GI on adiposity, glucose homeostasis 
and other metabolic parameters in the longer term. One study compared high and 
low GI diets matched for macro and micronutrients in mice up to the age of 40 
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weeks, an age equivalent to old age in humans (136). The high GI mice had lower fat 
oxidation, 40% greater adiposity and were more insulin resistant. Interestingly these 
effects were independent of energy intake since that was the same between the two 
diet groups. Similarly a study on 16 weeks and 44 weeks old mice (137) showed that 
the 16 weeks old high GI-fed mice had significantly higher body weight, increased 
fat mass and reduced insulin sensitivity. These outcomes were not as pronounced in 
the 44 weeks old high GI-fed mice indicating that the effect was greater in the 
younger years. 
 
Lastly, Scribner’s group conducted another study to understand the short (6 weeks) 
and long term (20 weeks) effects of high vs. low GI diets on body composition, liver 
fat, glucose clearance and lipid metabolism in mice (136, 138). All high GI-fed 
animals showed a significant increase in body fat mass, greater liver fat and elevated 
lipogeneses. In addition, the mice exposed to the high GI diet for longer were more 
insulin resistant than the low GI-fed mice, and in the postprandial state had a slower 
switch to carbohydrate and fat oxidation.  
 
1.5 Research aim and hypothesis 
In view of earlier findings (as reviewed above), the overall goal of this research 
project was to investigate the effects of a high and a low GI maternal diet on 
offspring metabolic markers and expression of two key genes (Fto and leptin) in an 
animal model. The primary outcome was the relative difference in Fto expression in 
offspring hypothalamus, the site of highest Fto expression and regulation of energy 
balance. The secondary outcomes included Fto expression in maternal placenta, 
leptin expression in offspring adipose tissue, growth rate, glucose and insulin 
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tolerance, plasma leptin and ghrelin concentration, and other measures related to 
appetite control. Our final aim was to examine histological liver samples in the 
offspring of high and low GI-fed mothers to determine how early exposure to 
postprandial hyperglycaemia may contribute to liver lesions and/or morphological 
alterations. The study design allowed for observations of both early-life and life-long 
exposure in response to the two carbohydrate-modified diets. 
 
Our hypotheses were: 
1. The offspring of high GI-fed mothers will be more glucose intolerant and/or 
insulin resistant than those of low GI-fed mothers. 
2.  The concentration of circulating appetite/satiety hormones in offspring plasma 
will be differentially influenced by the exposure to the two treatment diets. 
3. Fto gene expression in key tissues will be differentially regulated by the 
treatment diets. Specifically, Fto gene expression in the hypothalamus of pups of 
high GI-fed mothers will be higher than those of low GI-fed mothers, implying a 
direct epigenetic effect of maternal dietary GI. Fto gene expression in the 
placenta of the high GI-fed mothers will be higher than in low GI-fed mothers, 
providing a mechanism linking maternal with fetal expression.  
4. Leptin gene expression in the adipose tissue will be differentially regulated by 
the treatment diets. Specifically, leptin gene expression in the adipose tissue of 
pups of high GI-fed mothers will be lower than those of low GI-fed mothers, 
implying a direct epigenetic effect of maternal dietary GI on leptin gene 
regulation. 
5. High GI diet-fed offspring may present altered liver morphology due to greater 
glycogen and fat deposition resulting from postprandial hyperglycaemia.  
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6. Any adverse effects of early-life exposure to a high GI diet will be exacerbated 
by life-long exposure.  
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Chapter 2 
Investigating the effect of early-life and life-long exposure 
to a high vs. low GI diet on the metabolic phenotype  
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Chapter 2 Study design and rationale 
 
2.1 Introduction 
In 1990, Barker proposed the initially controversial hypothesis that human 
metabolism is programmed in utero (87, 88, 139, 140), that common chronic 
illnesses such as cancer, cardiovascular disease and diabetes result not always from 
‘bad’ genes and an unhealthy adult lifestyle, but from poor intrauterine and early 
postnatal health. Later described as the ‘developmental origins of health and disease’ 
(DOHAD), it is now one of the greatest arenas for experimental and clinical studies 
worldwide. In the space of a short timeframe, starting with the union of a sperm and 
an egg and finishing with birth, a single cell is transformed into a fetus. By birth the 
fetus has developed its own physiological attributes and the ability to live outside the 
womb. The developmental process is defined by the environment and the conditions 
in utero in which the embryo and fetus grow. Vulnerable stages of cell division and 
organ development are directly influenced by the conditions inside the womb.  
 
This environment, governed by fetal nutrition via the placenta, programs the 
distribution of cell types, hormonal feedback and metabolic activity. The nutrition of 
the mother plays a critical role. As early as 2000, there was evidence that even minor 
modifications to the maternal diet, both before and during pregnancy, changed the 
metabolism of the offspring (88). A similar effect was replicated with the “pup-in-a-
cup” model (141), thus becoming one of the most important examples of metabolic 
determination of the offspring by diet modification before and during pregnancy 
(142).  
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We now know that the mother’s diet shapes the metabolic programming of her fetus 
via specific modifications to genes, including histone modifications, gene hyper- or 
hypo-methylation or other pathways that are constantly being studied (95). 
Inappropriate fetal nutrition, orchestrated by the quantity and quality of nourishment 
obtained through the maternal–fetal interface, drive the future biological functions 
and health outcomes for the offspring (143). Langley-Evans described it thus: 
“Programming is the consequence of the innate capacity of developing tissues to 
adapt to the conditions that prevail during early life, which for almost all cell types in 
all organs is an ability that is present for only a short period before the time of birth” 
(97). 
 
Animal experiments have enabled us to observe these effects of maternal nutritional 
manipulation and their influence on the phenotype and metabolic profile of the 
offspring, as well as the later signs of metabolic syndrome in adult life (144). 
Furthermore, they have allowed us to discover that differential nutritional exposures 
can “program” or alter the epigenome (145, 146). These experimental findings are 
consistent with associations observed in humans.  
 
Fetal metabolism is largely based on the fetus’ principal energy substrate, glucose 
(105), which is transported across the placenta corresponding to the glucose 
concentration in the maternal circulation. The future offspring has an innate coping 
and adaptive capability to manage with changes in glucose supply, but these 
strategies may subsequently set the scene for metabolic disorders such as insulin 
resistance, obesity and diabetes mellitus (147). Gestational diabetes mellitus is one 
of the best examples of metabolic programming in utero. Intrauterine hyperglycemia, 
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leading to increased fetal plasma glucose and insulin concentrations, increases the 
rate of fetal growth, predisposing to high perinatal morbidity and mortality, as well 
as a long term predisposition to obesity, metabolic disorders and malignancy (117).  
 
However, even maternal glucose levels that are below the diagnostic values of 
diabetes have been associated with increased birth weight and cord-blood serum C-
peptide levels and hence fetal insulin levels (148). For this reason, diets which 
reduce postprandial glycaemia have the potential to improve pregnancy outcomes in 
normal women. Low glycaemic index (GI) diets are associated with reduced risk of 
type 2 diabetes and obesity-related disorders in prospective observational studies 
(128, 149, 150). Meta-analyses of randomized controlled trials show beneficial 
effects of low GI diets compared to high GI diets in overweight, obesity, type 2 
diabetes (151-153), and gestational diabetes (132, 133). 
 
Moses and Brand-Miller were the first to demonstrate that normal pregnant women 
following a lower GI diet had smaller infants with a lower ponderal index and 
reduced proportion of large-for-gestational age infants based on fetal centiles (130, 
154, 155). Since then, several other RCTs in overweight women (130, 156-158) and 
women with a history of macrosomia (159) have shown improved obstetric 
outcomes on a low GI diet.  Although birth weight is often used to gather 
information about the end point of fetal growth, it does not reflect the growth 
trajectory nor body composition (160) nor the metabolic health of the infant.  
However, observational studies also suggest that following a high GI diet in 
pregnancy adversely affects markers of the metabolic syndrome in the young adult 
offspring (134). 
- 54 - 
 
In designing the current study, we reasoned that an investigation of metabolic 
programming throughout pregnancy and early life required conditions and 
parameters that could be standardised and replicated.  Therefore in this study, we 
chose a mouse model to examine the impact of two commercial isocaloric diets 
matched for macronutrients and differing only in their glycaemic index (GI) on the 
male offspring of pregnant mice. In addition to growth and weight gain, our aim was 
to examine metabolic and physiological responses including glucose and insulin 
tolerance, plasma leptin, ghrelin, adiponectin and other hormones that may be 
affected by the difference in GI of the two diets. This kind of diets, have previously 
been tested in mice and rats in diet intervention trials showing effects on glucose 
tolerance, food intake, weight and adiposity (135, 136, 161). 
 
2.2 Materials and methods 
2.2.1 Animals and diets 
All animal work was approved by the Animal Ethics Committee of the University of 
Sydney (Protocol number L02/8-2010/2/5355). C57BL/6 mice were provided by the 
Animal Resources Center (Canning Vale, WA). Mice breeders were kept in indoor 
animal house facilities (temperature kept constant at 25
o
 C) in the School of 
Molecular Bioscience Animal House of the University of Sydney (Figure 2.1a). In 
general, two to six same sex mice were housed together in standard cages containing 
clean paper pellets and paper rolls to shred. Mice had ad libitum access to their feed 
and water through a feeder tray within the lid of the cage. The light-dark cycle of the 
animal holding room was 12 h-12 h.  
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Figure 2.1a Animal house facilities and cages. 
Photograph of the temperature-controlled cages. Food was placed in the insert of the 
cage and mice had ad libitum access. Water was always available through a bottle 
placed on top of the cage. 
 
Two special diets and a standard chow, were obtained commercially from Specialty 
Feeds, Glen Forest, WA, Australia. The two special diets were of identical 
macronutrient composition and calculated energy density, with only the starch 
component being different (Table 2.1). As described by the company, the starch was 
mechanically manipulated in order to obtain a ‘gel crisp’ high amylose starch for the 
Low GI diet (70% amylose, 30% amylopectin) and a dextrinised high amylopectin 
starch for the High GI diet (90% amylopectin, 10% amylose). Both starches were 
extracted from conventionally-bred varieties of maize (corn, Zea mays). The diets 
were enhanced with small amounts of AIN93 vitamin premix that used wheat starch 
instead of sucrose or glucose as the carrier. The diets were not irradiated (as was 
normal practice) because an earlier adverse event suggested that the process may 
have reduced the availability of micronutrients during pregnancy. The adverse event 
is described in Appendix 3. 
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Figure 2.1b The High GI and Low GI feeds used in this study. 
The High GI and Low GI feeds were matched for macro- and micro-nutrients and 
had similar appearance, texture and colour. 
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Table 2.1. A comparison of the main nutrients in the two special feeds and the 
chow diet. A more comprehensive table with the full nutritional information panel of 
each treatment diet can be found in Appendix 2. 
 
 
2.2.2 Study design 
A schematic representation of the design of the first study is shown below. 
 
  
LOW 
GI   
 
HIGH 
GI 
 
CHOW 
Protein (g/100 g)  19.40 19.40 19.60 
Total Fat (g/100 g)   7.00 7.00 4.60 
Crude fibre  (g/100 g) 4.70 4.70 4.50 
AD fibre (g/100 g)   4.70 4.70 Not 
specified 
Digestible energy (MJ/kg)  16.3  16.3  14.3 
Total calculated digestible energy from lipids (g/100 g)  16.00 16.00 Not 
specified 
Total calculated digestible energy from protein (g/100 g)  21.00 21.00 Not 
specified 
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C57BL/6 female mice (n = 21) were delivered to the Animal House at 4 weeks of 
age and randomly assigned to one of the following diet groups: Low GI diet (LGI), 
High GI diet (HGI) and Standard Chow (CC) (7 female mice for each group). 
C57BL/6 male breeders were delivered at 3 weeks of age and consumed CHOW for 
the 4 weeks prior to mating. At this point, their diet was interrupted briefly (~ 15 h) 
when they were placed in female cages.   
 
Mating was based on the “Breeding Strategies for Maintaining Colonies of 
Laboratory Mice”, Resource Manual by the Jackson Laboratory 
(http://jaxmice.jax.org/manual/#breeding). At birth only male pups were kept for this 
research. Female mice were made available to other researchers.  
 
Male pups from the LGI and HGI groups were weaned at the beginning of week 5 
and were further divided into two subgroups, one following their mother’s diet (LL 
and HH) and one following the CHOW diet (LC and HC). Male pups of the CHOW 
group were weaned at the same time and continued on CHOW (CC). This last group 
has been used as the group of reference and comparison for our analysis. 
 
2.2.3 In vitro GI testing of diets  
An in vitro starch digestion assay described by Englyst et al. (162) as ‘a method that 
predicts the glycaemic response’ was performed in triplicate. Rapidly available 
glucose (RAG) and slowly available glucose (SAG) were measured in order to 
describe the rate at which glucose from each diet became available for absorption.  
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Briefly, the in vitro digestion of starch from the high and low GI feeds was 
determined in duplicate samples. An enzyme solution was prepared by suspending 
0.45 g of porcine pancreatic α-amylase (150 U/mg, Sigma A3176) in 16 mL of water 
with magnetic stirring for 10 min at 37 °C. The mixture was centrifuged (1,500 × g 
for 10 min) and 2 mL of amyloglucosidase (3,260 U/ml, Megazyme) was added to 
10.8 mL of the above enzyme supernatant. The feeds were crushed into a fine 
powder using a laboratory mortar and pestle, and the corresponding amount 
containing 100 mg starch (dry weight) was dispersed in 4 mL of 0.1 M sodium 
acetate buffer (pH 5.2). After adding 1 mL of the freshly prepared enzyme solution, 
the mixture was incubated in a shaking water bath (37°C, 160 strokes/min). Aliquots 
(0.1 mL) were taken at the same time intervals as for GI testing and mixed with 1 
mL of 95% ethanol. The glucose released was measured by the glucose oxidase-
peroxidase reagent according to the supplier’s instructions (Megazyme International 
Ireland Ltd. Bray Co., Wicklow, Ireland). 
 
2.2.4 Identification by ear-marking 
At 4 weeks of age, male pups were anaesthetised using isoflurane (ISO) solution 
within a glass chamber.  A surgical scissor was used to obtain one of six unique ear 
punches (three sites for the right and three sites for the left ear). 
 
2.2.5 Food intake and weight monitoring 
After weaning, the pup weights were recorded weekly using an electronic laboratory 
scale, until 20 weeks of age when they were sacrificed. Three 24 h food intake 
observations were conducted at weeks 9, 12 and 16. Mice were placed in custom 
made cages that contain an insert to allow catching spilled food.  The experiment was 
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conducted according to cage grouping (n = 2-5 per group) to minimize stress of 
individual housing. Food intake measurements were recorded by weighing food 
pellets before and after 24 h and dividing by the number of mice in the cage.  Any 
food spilled into the bottom of the cage was subtracted. 
 
2.2.6 Glucose tolerance test  
An intraperitoneal Glucose Tolerance Test (GTT) was conducted at week 17. Mice 
were fasted for 4-6 hours prior to testing (163, 164). Basal blood glucose levels were 
tested using an Accu-Check Performa glucometer (Roche Diagnostics Australia Pty 
Ltd) through a small incision on the tail. Mice were subsequently administered 
glucose (2 mg/g body weight of 50% w/v solution) via an intraperitoneal injection. 
Blood glucose levels were determined at 15, 30, 45, 60, 90 and 120 min after first 
injection and the incremental area under the curve (iAUC) was calculated in 
accordance with the method recommended by Wolever (165). 
 
2.2.7 Insulin tolerance test 
An intraperitoneal Insulin Tolerance Test (ITT) was conducted at week 18. Mice 
were fasted for 4-6 hours prior to testing. Basal blood glucose levels were tested 
using an Accu-Check Performa glucometer (Roche Diagnostics Australia Pty Ltd) 
through a small incision on the tail. Mice were subsequently administered insulin 
(Actrapid Novo Nordisk Pharmaceuticals Pty Ltd. 1U/kg body weight) via an 
intraperitoneal injection. Blood glucose levels were determined at 15, 30, 45, 60, 90 
and 120 min after first injection. In the case of mice with very low readings at any 
point of the ITT, a glucose solution was injected and the animal removed from the 
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experiment. This was necessary in order to avoid coma or death due to 
hypoglycaemia. 
 
The primary outcome was the rate of decline of glucose during the first 30 min after 
insulin injection. The rate was calculated from the slope of the line and interpreted as 
a measure of insulin sensitivity. 
 
2.2.8 Mouse sacrifice, blood and tissue collection 
At 20 weeks of age, mice from all groups were sacrificed by intraperitoneal injection 
with 100 µl of Lethabarb euthanasia solution. Mice were previously fasted for 4-6 
hrs. Sacrifice took place in the surgery room of the Animal House away from other 
animals to avoid stress. After the injection, mice were observed until assured they 
were dead by absence of respiratory movement and corneal reflex. 
 
With a cardiac puncture, blood was collected in sterile heparin coated tubes and 
separated by centrifugation (10000rpm, 1 min, 25
o
C, Eppendorf Centrifuge 
MiniSpin®). Plasma was transferred to a fresh tube, snap frozen in liquid nitrogen 
and stored at -80
o
C until further analysis.  
 
The following tissues were collected: hypothalamus, brown adipose tissue (BAT), 
liver, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), red muscle 
(RM) and white muscle (WM). A sample from each liver tissue was fixed in 4% 
(w/v) phosphate-buffered paraformaldehyde for 48 hours at 4
o
C. Then tissues were 
transferred to phosphate-buffered saline solution and subsequently embedded in 
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paraffin and sectioned to allow for histological tests. Collected tissues were snap-
frozen in liquid nitrogen and stored at  -80
o
C until further analysis. 
 
2.2.9 Plasma analysis 
Plasma samples collected at sacrifice were analysed by ELISA using a Multiplex 
Map Kit by Cardinal Bioresearch Pty Ltd (New Farm, Qld, Australia). Protease 
inhibitors were added during sample thawing. The following hormones were 
measured: ghrelin, leptin, adiponectin, insulin, Glucagon-like peptide 1 (GLP1), 
pancreatic polypeptide (PP), peptide YY (PYY), adrenocorticotropic hormone 
(ACTH), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFɑ). 
 
2.2.10 Statistical analysis 
Data were statistically analysed using SPSS Statistics 19 (IBM) and Prism 6.0 
(Graph Pad Software, USA). A one-way repeated measures analysis of variance 
(ANOVA) and two-tailed unpaired t-tests were performed to assess the difference 
between the studied variables amongst the groups. A normal distribution could be 
assumed for most variables but in the case of plasma hormone levels, a large within 
group variability was observed and significant deviation from normality was found, 
thus Kruskal–Wallis and Mann-Whitney U non parametric tests were used. 
 
These comparisons were made in order to investigate the effect of varying exposure 
to the High GI, Low GI and CHOW diets, and more specifically to investigate the 
effects of: 
a. Early-life exposure to the diet  (comparison of HC and LC groups) 
b. Extended (life-long) exposure to the diet  (comparison of HH and LL groups) 
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Due to the large number of variables, a statistical p value of ≤ 0.05 was taken as 
marginal significance and p ≤ 0.01 as statistically significant.  
 
2.3 Results 
2.3.1 Rate of digestion in vitro 
A validated in vitro starch digestion assay was used as an indicator of the likely 
glycaemic response to each of the diets (162). The results (Figure 2.2) show that at 
the 20 min time point, the amount of rapidly available glucose (RAG) in the High GI 
feed was 55.6% higher than the Low GI feed (p = 0.006). Similarly, at 120 min of 
digestion, the amount of glucose released was 43.6% higher in the high GI feed (p = 
0.0006). This trend continued for the whole testing period of starch digestion. 
 
 
Figure 2.2 Rate of starch digestion for the High GI feed (
____
) and the Low GI 
feed (
____
).  Rate of digestion was determined by the Englyst procedure (162). Both 
feeds were tested in duplicate on three occasions, using 1 g of finely powdered pellet.  
RAG = G20 – G0. The High GI feed had an excess of 93 mg of glucose per gram of 
feed available for absorption compared with the low GI feed at 20 min. SAG = G120-
0
100
200
300
400
500
600
700
0 20 120 150 180
m
g 
G
lu
/g
 
time 
High GI
Low GI
P = 0.006 
P = 0.0006 P = 0.007 
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G20. The Low GI feed had 102 mg/g less glucose available for absorption and 
demonstrated an overall slower starch digestion over the 180 min period. 
 
2.3.2 Food intake 
In this study there were no differences in litter size (average n = 7) or conception rate. 
After weaning, male pups in each litter were subdivided into two diet groups. 
Overall five diet groups were created with chow diet being used as a control group. 
Figure 2.3 summarises the abbreviations used for the five diet groups and the 
number of pups in each group.  
 
 
 
Figure 2.3 Diet groups after weaning. 
CC : pups of the chow diet mothers that continued on chow after weaning 
HH: pups of the High GI diet mothers that continued the High GI diet after weaning 
HC: pups of the High GI diet mothers that were weaned to a chow diet 
LL: pups of the Low GI diet mothers that continued the Low GI diet after weaning  
LC: pups of the Low GI diet mothers that were weaned to a chow diet 
 
Food intake was measured at week 9, 12 and 16 (Figure 2.4). The highest food intake 
was observed in week 9 for the CC and HC groups whereas the LL group showed 
the lowest intake, but there were no significant differences at any time point. 
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Similarly, at week 12 the HH group had the highest food intake (3.7 g/mouse/day) 
compared to all other groups, whereas the LL group had the lowest (3 g/mouse/day) 
but overall, the differences among the groups did not reach statistical significance (p 
= 0.4). In week 16 all groups showed very similar intake. 
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Figure 2.4 Average food intake. Values expressed as average g per kg of body 
weight. Chow n = 12, HC n = 12, HH n = 13, LC n = 12, LL n = 10. All data 
represent mean ± SEM. (NS = not significant).  
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2.3.3 Body weight 
Body weights of the pups were measured at weekly intervals from 5 to 20 weeks of 
age. Figure 2.5 shows the weights at week 5 just before weaning. There was no 
significant difference in mean weight between CC and the treatment groups HGI and 
LGI.  Body weight progression was similar in all groups. At weeks 16 and 19, LC 
showed a slightly higher (+ 7%) body weight than the HC group (p = 0.005) (Figure 
2.6 A). All groups were comparable with the average body weight of ~31.4 g (±2.4) 
at week 19, similar to that described by the animal breeder (Jax® Mice and Services) 
(http://jaxmice.jax.org).  
 
Figure 2.5 Male C57BL/6 pups body weights at week 5. 
Pups of CC (n = 13), HGI (n = 28) and LGI mothers (n = 24). Data are expressed as 
mean ± SEM. Weights were recorded weekly to the nearest 0.1 g. (NS = not 
significant). 
 
Subsequent comparisons between the groups were made in order to investigate the 
effect of varying exposure to the High GI, Low GI and CHOW diets, as shown in 
Figures 2.6 and 2.7: 
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A. Early-life exposure to the diet  (comparison of HC and LC groups) 
B. Extended (life-long) exposure to the diet (comparison of HH and LL 
groups) 
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A 
 
B 
 
Figure 2.6 Body weight progressions from week 5 to week 20. Data are expressed 
as mean ± SEM. A and B: no significant differences (NS) were observed at any time 
point. CC n = 13, HC n = 13, HH n = 15, LC n = 13, LL n = 11. 
At week 20, immediately prior to sacrifice, LC were slightly heavier (+ 6.9%) than 
HC mice, (reaching the greatest average weight overall of 31 g) but the difference 
did not reach statistical significance.  
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Figure 2.7 Body weights at week 20 just prior to sacrifice. Data are expressed as 
mean ±SEM. No significant difference was observed. CC n = 13, HC n=13, HH n = 
15, LC n = 13, LL n = 11. NS = not significant. 
 
2.3.4 Glucose tolerance test 
Intraperitoneal glucose tolerance tests (ipGTT) were conducted to investigate 
differences in glucose tolerance among the groups. After injection at 0 time, plasma 
glucose levels were determined at 0, 15, 30, 45, 60, 90 and 120 min. The incremental 
area under the curve (iAUC) was calculated and results are shown in Figures 2.8 and 
2.9.  
 
Overall, there were no significant differences in plasma glucose responses between 
the HC and LC groups, although the peak at 15 min was slightly higher in HC than 
LC (Figure 2.8A, p = 0.08). At 30 min, the HH group had marginally higher glucose 
levels than the LL group (p = 0.02), suggesting slower glucose clearance in HH, but 
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other time points were similar (Figure 2.8B). There were no significant differences in 
incremental area under the curve (iAUC) in HH vs. LL (Figure 2.9).  
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Figure 2.8 Plasma glucose responses to the intraperitoneal glucose tolerance test.  
Blood glucose readings were performed after intraperitoneal glucose injection. Data 
represent mean ± SEM. A: no significant differences were observed. B: marginal 
significant difference at 30 min (p = 0.02). CC n = 8, HC n = 10, HH n = 10, LC n = 
13, LL n = 10. 
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Fig 2.9 Plasma glucose incremental area under the curve (iAUC). Data 
calculated from plasma glucose curve from ipGTT representing mean ± SE. No 
significant differences were observed. CC n = 8, HC n = 10, HH n = 10, LC n = 13, 
LL n = 10. NS = not significant. 
 
2.3.5 Insulin tolerance test 
An intraperitoneal insulin tolerance test (ipITT) was performed to investigate insulin 
sensitivity. Insulin was injected and the rate of decrease in plasma glucose levels 
observed. The slope of the line between 0 and 30 min of the testing period can be 
used as a measure of insulin action. 
 
Overall, there were no significant differences in insulin tolerance between HC vs. LC 
or HH vs. LL (Figure 2.10). Blood glucose at 30 min and at 45 - 120 min (p > 0.1) 
tended to be lower in the high GI groups (HC and HH) but this did not reach 
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statistical significance. CC had significantly lower plasma glucose levels at 0 min 
than LC and LL groups (p ≤ 0.01).  
A 
 
B 
 
Figure 2.10 Plasma glucose levels after intraperitoneal insulin injection. Data 
shown represent mean ± SEM. A: C vs. LC p = 0.004, C vs. HC p = 0.037.  B: C vs. 
LL p = 0.001 and HH vs. LL at 45 – 90min p > 0.01. CC n = 7, HC n = 7, HH n = 12, 
LC n = 7, LL n = 10.  
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Figure 2.11 shows the average slope observed during the first 30 min after the intra-
peritoneal insulin injection. No significant difference was observed among the 
groups. 
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Figure 2.11 Average slope of plasma glucose levels in the first 30 min of ipITT. 
Data shown represent mean ± SEM. There were no significant differences between 
the groups. CC n = 7, HC n = 7, HH n = 12, LC n = 7, LL n = 10. NS = not 
significant.  
 
2.3.6 Plasma hormones analysis 
Plasma samples collected with a cardiac puncture at sacrifice were analysed using an 
enzyme-linked immunosorbent assay (ELISA) and the following hormones were 
measured: ghrelin, leptin, adiponectin, insulin, PYY, GLP-1, PP, ACTH, IL6 and 
TNFɑ. Only cardiac plasma samples that were equal or above 200 µl were used, and 
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therefore the number of samples per group vary. In our analysis, no outliers were 
found. 
 
Figure 2.12 shows the average values of ghrelin detected in the plasma samples. 
Ghrelin levels in the CC group were almost 4-fold higher than LC pups (p = 0.04) 
but there were no significant differences between HC and LC. In contrast, ghrelin 
was 150% higher in HH compared to LL, although the difference was only 
marginally significant (p = 0.02). Overall, ghrelin levels were 2-fold higher (+126%) 
in groups exposed to high GI feeding (HC + HH) vs. low GI feeding (LC + LL, p = 
0.02). 
 
Leptin plasma levels were significantly higher (+525%) in the LL group compared to 
HH (p = 0.001, Figure 2.13). No significant statistical difference was observed 
among the other groups.  
 
Adiponectin levels in the LC group were ~33% higher than HC, but this did not 
reach significance (p = 0.1, Figure 2.14). There was no significant difference 
between HH and LL. The CC group showed the highest adiponectin levels (CC vs. 
HC and HH, p = 0.008).  
 
Plasma insulin levels are shown in Figure 2.15 below. CC had the highest mean 
concentration and HH the lowest, but none of the differences was significant.  
 
 
- 77 - 
 
 
Figure 2.12 Plasma ghrelin levels in 20 week old mice obtained by cardiac 
puncture. Data shown represent mean ± SEM. CC n = 6, HC n = 8, HH n = 8, LC n 
= 8, LL n = 8. 
 
Figure 2.13 Plasma leptin levels in 20 week old mice obtained by cardiac 
puncture. Data shown represent mean ± SEM. CC n = 6, HC n = 8, HH n = 8, LC n 
= 8, LL n = 8. 
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Figure 2.14 Plasma adiponectin levels in 20 week old mice obtained by cardiac 
puncture. Data shown represent mean ± SEM. CC n = 6, HC n = 8, HH n = 8, LC n 
= 8, LL n = 8. 
 
Figure 2.15 Plasma insulin levels in 20 week old mice obtained by cardiac 
puncture. Data shown represent mean ± SEM. No significant differences were 
observed among the groups. CC n = 6, HC n = 8, HH n = 8, LC n = 8, LL n = 8. NS 
= not significant. 
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Glucagon-like peptide 1 (GLP1), pancreatic polypeptide (PP) and peptide YY (PYY) 
were also analysed (Figure 2.16). GLP1 levels varied over a 2-fold range, but the 
difference between HH and LL did not reach significance (p = 0.07).  Similar results 
were obtained for PP and PYY concentrations, where none of the differences among 
the groups reached statistical significance.   
 
Finally, Figure 2.17 shows the results for adrenocorticotropic hormone (ACTH), 
interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFɑ) respectively. Although 
there was some variation among the groups, none of the differences reached 
statistical significance.  
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Figure 2.16 Plasma GLP-1, PP, PYY levels in 20 week old mice respectively. 
Data shown represent mean ± SEM. No statistically significant (NS) differences 
were observed. For all three hormones: CC n = 5, HC n = 8, HH n = 8, LC n = 8, LL 
n = 8. NS = not significant. 
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Figure 2.17 Plasma ACTH, IL6, TNFɑ levels in 20 week old mice respectively. 
Data shown represent mean ± SEM. No statistically significant (NS) differences 
were observed. For all three hormones: CC n = 6, HC n = 8, HH n = 8, LC n = 8, LL 
n = 8.
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2.4 Discussion 
In this chapter, contrary to our hypothesis, we were not able to show an association 
of dietary GI with food intake, body weight, glucose tolerance or insulin sensitivity.  
However, the present study did show that life-long exposure to a low GI diet impacts 
on plasma ghrelin (an orexigenic hormone) and leptin levels (an anorexigenic 
hormone). Ghrelin concentration was higher in mice exposed to the high GI diet, 
suggesting greater hunger overall, while leptin levels were lower, suggesting lower 
satiety. Together these hormonal differences suggest that a high GI diet increases the 
risk of overconsumption, although we could not detect differences in food intake or 
body weight up to 20 weeks of age. These associations were highly significant in 
pups continuously exposed to a high GI diet after weaning (HH), but the same trend 
was evident (but without reaching statistical significance) even in the early-life 
exposed pups (HC). These findings suggest that carbohydrate nutrition and/or 
glycaemic exposure has subtle effects during the gestational period that may not be 
revealed until later in adulthood. Circulating levels of the anorexigenic hormone 
leptin and orexigenic hormone ghrelin have been shown to play a crucial role in the 
development of overweight and obesity through hunger / appetite control and energy 
balance (166).  
 
2.4.1 Rate of digestion in vitro 
In humans and animal models the rate of starch digestion and absorption has been 
shown to be an excellent predictor of the glycaemic response to a starchy meal (167, 
168). Englyst et al. (162) developed an in vitro methodology to measure the amount 
of rapidly available glucose (RAG) in a food sample, using digestive enzymes under 
standardized conditions. RAG is defined as the glucose released from starch within 
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the first 20 min of digestion. Slowly available glucose (SAG) is defined as the 
glucose released between 20 and 120 min. Resistant starch is the fraction that 
remained undigested after 120 min. Englyst’s group has shown that RAG is more 
highly correlated than SAG to the glycaemic response elicited by different foods. 
Since then, Englyst’s methodology has been widely used to predict GI values of 
unknown foods (169-171). 
 
Amylose content, particularly the amylose/amylopectin ratio (172, 173), is known to 
have a direct impact on starch hydrolysis and digestibility. The two special diets 
provided by Specialty Feeds Pty Ltd were therefore formulated with same starch 
content, but differing in the amylose/amylopectin ratio. The in vitro testing allowed 
us to test and confirm that the two diets contained starches with different rates of 
digestion. At both 20 min and 120 min the high GI diet released a significantly 
higher amount of glucose compared to the low GI diet. Since RAG is the best 
predictor of the glycaemic response, at least in humans, we predicted that the High 
GI diet was likely to have produced a higher postprandial response than the Low GI 
diet in the mice participating in our experiment.   
 
The 120 min in vitro results indicate that the Low GI diet contained a higher portion 
of starch that is fairly resistant to digestion, at least in humans. However, it is 
possible that mice digest raw starch to a much greater extent because they have 
evolved on native diets contained uncooked cereal grains. Nonetheless, it could be 
argued that fewer calories were available to the mice on this feed.  If true, we might 
expect to have seen differences in rate of growth or food intake. However, we found 
similar food intake and no important differences in body weight between treatment 
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groups at 20 weeks of age. Thus, any metabolic differences between groups can be 
reasonably ascribed to lower postprandial glycaemia throughout the lifespan of these 
mice. We do not exclude though, the possibility that the Low GI feed could reduce 
overall calorie intake, alter body composition and be less obesogenic because it 
contains proportionately more resistant starch.  
 
2.4.2 Food intake and metabolic profile  
In the male pups, we conducted 24 h food intake measurements in triplicate at 
different ages to estimate average food intake in each diet group. Overall there were 
no significant differences in food intake at any time between the groups. This 
indicates that in the current study the GI of the maternal and offspring diet did not 
affect food intake for the first 16 weeks of life. We anticipated that the low GI-fed 
mice might consume less feed because the satiety potential of the low GI diet has 
been shown to be higher in some studies, but our data did not support this.  It is also 
possible that the low GI diet contributed fewer kilojoules because some starch was 
resistant to digestion. However, the starting weights at weaning (week 5) did not 
differ significantly among the pups of the CHOW, High and Low GI-fed mothers 
and their progression remained similar for the rest of their development. In particular, 
looking at the extended exposure to the treatment diets (HH vs. LL), it is obvious 
that there was virtually no difference in body weight for the whole 20 week period.  
 
These findings are in agreement with a previous study (136) investigating the long 
term effects of a high and low GI diet in mice. The body weight of the two treatment 
groups throughout the 38 weeks of observation did not differ significantly. Similarly 
energy intake calculated through the use of stools after a food intake observation 
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period, did not differ between the high and low GI-fed mice. In contrast, Isken et al. 
(174) showed that long-term exposure (up to 20 weeks) to a high vs. low GI diet 
leads to a moderate but significant increase in body weight in the high GI-fed 
C57BL/6 mice. However in the current study, a higher fat content in the high and 
low GI feeds may have produced the expected differences in phenotype.  Previous 
studies have indicated that fat is the crucial stimulus for overconsumption, obesity 
and diabetes-related parameters in C57BL/6 wild-type mouse (175, 176). 
 
A limitation of the current study is that we did not collect faeces or determine faecal 
energy in the mice during the 24h food intake experiment. Similarly, in the absence 
of data regarding oxygen consumption and carbon dioxide expiration, we were not 
able to determine net energy intake and expenditure. Our food intake measurements 
were made in triplicate at different ages but were based on group intake rather than 
individuals. We did this so as not to increase the stress levels of the mice, a factor 
known to alter appetite (177). However, even under these conditions, the mice may 
have altered their normal day to day eating pattern and some mice could have been 
affected more than others. This means that the average food intake results should be 
treated with caution. Maternal food intake and body weights would also have been 
informative, but we were wary of disturbing the mothers due to the serious adverse 
event that we faced previously (Appendix 3). Likewise, body composition 
measurements (total body fat, epidydimal fat) of the pups would have provided 
important insights but were not the focus of our study.  
 
In our rodent model of early-life and life-long exposure, glucose clearance during the 
ipGTT was similar amongst pups exposed to the CHOW, High or Low GI diet. The 
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iAUCglucose were not significantly different, but there was some evidence that glucose 
levels were lower in the LL group. At the critical time of 30 min (the peak) plasma 
glucose concentration was significantly lower in the LL vs. HH group, suggesting 
faster glucose clearance in those exposed continuously to a low GI from conception 
to 17 weeks of age.  
 
Similarly, during the ipITT we did not observe any significant difference in the rate 
of glucose decline (measured as the slope of the line between 0 time and 30 min) 
between the groups. But there was some evidence that the life-long low GI-fed pups 
(LL) were less sensitive to the insulin injected. Although this is usually interpreted 
as greater insulin resistance, it could be argued that the HH group has an inferior 
counter regulatory system that resulted in greater glucose fluctuation. Thus the LL 
group (and to some extent the LC group) may cope better with metabolic stress (in 
this case, a carbohydrate challenge), with avoidance of wide fluctuations in blood 
glucose levels.   
 
Our findings in regard to GI and glucose homeostasis are in agreement with some 
studies but not others. Scribner et al. (136) reported no differences between 
glycaemic AUC following an oral GTT test in mice fed low and high GI diets, 
whereas Isken et al. (174) observed lower glucose AUC (i.e. greater glucose 
tolerance) in the low GI-fed mice but no difference in insulin AUC. Coate and 
Huggins (178) reported that low GI-fed mice, independently of the fat content of the 
diet, had lower glucose AUC than high GI-fed mice. In this case, the test conducted 
was a meal tolerance test instead of an intraperitoneal glucose and insulin challenge. 
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With 10-13 animals per diet group, our study was appropriately powered to detect 
biologically important differences in glucose tolerance and insulin sensitivity. 
However, the results and differences could have been influenced by the fact that for 
both the GTT and ITT, the amounts of glucose and insulin injected were calculated 
on the body weight of the pups and not their body lean mass (a more appropriate 
parameter for the study of metabolism). Although the experiments were conducted 
carefully, the Accu-check™ glucometer that was used in both experiments is not 
designed for animal use. It is not as accurate at blood glucose levels >20 mM, a 
concentration that is commonly exceeded in mice during a GTT.  These weaknesses 
may have meant that true differences between the groups have gone undetected. 
 
We did not find any significant differences in adiponectin or insulin plasma levels. 
There was a tendency for CC, LC and LL groups to display higher plasma 
adiponectin but these observations did not reach statistical significance. These 
outcomes are in agreement with a human study on the effect of low- and high- GI 
diets on chronic disease susceptibility biomarkers (127). A first analysis of their data 
indicated there were no statistical differences in the adiponectin levels by diet 
treatment, though a small difference (where low GI diet was associated with higher 
adiponectin concentration) was noted. After a stratified analysis by body fat mass, 
adiponectin increased significantly in the overweight/obese individuals that followed 
a low GI diet. Thus, their outcome resembles the higher adiponectin trend we 
observed in the chow and low GI fed healthy weight mice. It may be speculated that 
if there were overweight or obese mice in our study, adiponectin levels might have 
been significantly different between the low and high GI groups. In contrast, our 
fasting plasma insulin result contrasts that of a previous study in mice by van 
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Schortorst et al. (175) that showed significantly lower insulin levels in the low GI 
group. 
Likewise, although there were some variations in the plasma levels of GLP-1, PP, 
PYY, ACTH, IL6 and TNFɑ between the groups, no significant differences were 
observed. A recent review on the effect of low vs. high GI diets on selected 
biomarkers (179) indicated inconsistent results. The human studies that were 
designed to maintain constant body weight showed that GLP-1, IL-6 and TNFɑ were 
not significantly affected by the GI values of the diet. However, in one study 
intended to induce weight loss, the low GI diet was associated with lower IL-6 and 
TNFɑ concentrations. The authors of the review acknowledged that formulating 
dietary recommendations between the GI and these biomarkers is premature due to 
the inconsistencies in the literature. Similarly, for PYY, ACTH and PP, to our 
knowledge there are no investigations conducted after meal testing (180, 181) 
making the comparison to our data difficult.  
 
Finally, this study showed that life-long exposure to a high GI diet vs. low GI diet is 
associated with higher (+148.6%) ghrelin plasma levels and significantly lower (-
525%) leptin levels. Even though we were not able to show a significant impact on 
ghrelin and leptin in the early-life exposed pups (HC and LC), they displayed a 
consistent and similar trend to that observed in the life-long exposed pups.  Thus we 
argue that in both cases, early-life nutrition appears to play a role. To our knowledge 
these findings are novel. One study in mice reported higher leptin levels in the high 
GI-fed group (178). However, the diet composition was simultaneously altered for 
fat content and body fat may have been higher (and therefore leptin). In a human 
study, after 12 weeks of dietary intervention, a low GI diet significantly decreased 
- 89 - 
 
leptin levels compared to a high GI diet (182). However, as this was a weight loss 
study, the changes in leptin were also correlated to reductions in fat mass. We 
believe our finding is reliable because plasma assays were conducted in duplicate 
using automated multi-level ELISA and in a large sample size for each diet group.  
 
Since ghrelin is an important hormone for the stimulation of appetite, while leptin is 
the major satiety and appetite control hormone, our discovery has significant 
implications. Greater hunger before meals and less satiety between meals, even of a 
modest degree, are likely to spell more frequent and higher food intake over the 
longer term.  
 
Huda et al. (183), in an investigation of the effects of ghrelin on appetite and energy 
expenditure in lean, obese and post-gastrectomy subjects, showed that the levels of 
ghrelin around traditional mealtimes play a significant role in the continuous 
‘grazing’ pattern that is seen in obese subjects. Furthermore, in a very rare human 
condition that is congenital leptin deficiency, Farooqi et al. (184) showed that before 
and after 7 days of treatment with recombinant human leptin, treatment had a major 
effect on food intake. After leptin treatment, hunger ratings in the fasted state 
decreased, and satiety following a meal increased. Their experiment provided 
functional neuroanatomical insights into the mechanisms by which leptin, can 
interact with the recent ingestion of food to modulate spontaneous eating behaviour 
in humans. 
 
In summary, contrary to our hypothesis, we were not able to show an association of 
dietary GI with food intake, body weight, glucose tolerance or insulin sensitivity.  
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However, our study demonstrated that extended exposure to a low GI diet increases 
circulating leptin levels and decreases ghrelin levels, an effect that is probably 
programmed already in utero. Together, the findings suggest that maternal and 
offspring diets that raise postprandial glycaemia, even within the normal range, have 
the capacity to program the metabolism of offspring in a manner that predisposes to 
overweight.  
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Chapter 3 
Investigating the effect of early-life and life-long exposure 
to a high vs. low GI diet on FTO and leptin gene expression 
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Chapter 3 Study design and rationale 
 
3.1 Introduction 
The current epidemic of obesity has been often linked with the increased availability 
of energy-dense foods, sedentary lifestyles and genetic predisposition. This theory 
has not satisfied many in the scientific world because it does not explain the sudden 
increase in obesity observed in children and young adults (185). Increasingly 
convincing evidence supports the developmental origins of adult health and disease 
hypothesis, that is, that the origins of obesity and other chronic diseases lie in the 
early pre- and post-natal environment. Specifically, different nutritional exposures 
during the early developmental period, including fetal life and lactation, influence 
predisposition to the metabolic syndrome and obesity later in life (186).  
 
A nutritional stimulus or insult during the critical period of organogenesis (fetal 
development) and immediate postnatal maturation (suckling) can have lasting 
programming effects. In  pregnancies complicated by diabetes, hyperglycaemia in 
the early stages of pregnancy results in the up-regulation of the glucose transporters 
and leads to an accelerated fetal growth during late gestation (143). In turn, this leads 
to increased risk of child obesity and type 2 diabetes in young adulthood (110, 148, 
187). 
 
In rat studies, zinc deficient dams produce offspring that weigh less than controls at 
birth and up until six months of age, but have a higher body fat ratio. Maternal zinc 
restriction induced fasting hypoinsulinaemia in the offspring and impaired insulin 
response to a glucose challenge (188). Patel and colleagues have summarised studies 
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showing the interaction between early life nutrition and metabolic programming 
(Table 3.1) (186). Thus nutritional stress or nutritional adequacy clearly influence 
metabolic imprinting. Effects can be either negative or positive outcomes in different 
stages of life, from conception to the post- weaning period and later in life.  
 
The endocrine mechanisms that develop in suboptimal intrauterine conditions are 
thought to program metabolism throughout life. The main site where the defence 
response to stress is located is the hypothalamic-pituitary-adrenal axis (HPA). 
Exposure to physiological stresses  during early stages of development are thought to 
create a pattern of stress response in the HPA that will follow the fetus throughout its 
neonatal and adult life (189). 
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Table 3.1 Summary of the metabolic programming effects induced by an 
altered experience in the immediate postnatal life. From Patel et al 2009 (186). 
A. Undernourishment (large-sized litter rat model) 
 Reduced body weight gains for life 
 Reduced fasting plasma insulin levels 
 Reduced insulin secretory response to a glucose stimulus 
B. Overnourishment (small-sized litter rat model) 
 Increased body weight gain beginning from the suckling period accompanied by 
hyperphagia.  
 Increased plasma levels of insulin and leptin for life 
 Augmented insulin secretory response by isolated islets to a glucose stimulus 
 Altered responses by brain slices to various stimuli such as insulin, leptin and several 
neuropeptides 
C. The HC rat model (qualitative change in the nutrition) 
a. Immediate effects (pre-weaning period) 
 Immediate increase in plasma insulin levels 
 Reduced plasma leptin levels 
 Normal plasma glucose levels 
 Leftward shift in the response to a glucose stimulus 
 Increased expression of the preproinsulin and related transcription factor genes 
 Increased insulin biosynthesis 
 Altered pattern of several clusters of genes 
 Increased number of small-sized islets 
 Increased number of islets per unit area 
 Modifications in the ANS regulation of insulin secretion 
 Increased mRNA levels of orexigenic neuropeptides 
 Decreased mRNA levels of anorexigenic neuropeptides 
 Increased protein content of neuropeptide Y 
 Increased hepatic lipogenic capacity 
b. Persistent effects (post-weaning period) 
 Persistence of hyperinsulinaemia 
 Hyperphagia resulting in adult-onset obesity 
 Abnormal response to a glucose tolerance test 
 Leftward shift to a glucose stimulus 
 Increased gene expression of preproinsulin 
 Alterations in several clusters of genes 
 Increase in insulin-producing mass 
 Modifications in the ANS regulation of insulin secretion 
 Increased mRNA levels of orexigenic neuropeptides 
 Decreased mRNA levels of anorexigenic neuropeptides 
 Increased neuropeptide Y protein content 
 Alteration in the protein levels of the proximal insulin signalling components 
 Increased lipogenic capacity of liver and adipose tissue 
 Increase in the size of the adipocytes 
c. Generational effects 
 Spontaneous transmission of the HC phenotype to the offspring 
 Metabolic programming effects initiated during fetal development 
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The field of epigenetics has been defined as the study of “heritable changes in gene 
function that cannot be explained by changes in DNA sequence” (190). Without 
affecting the genotype the cell phenotype can be altered via structural adaptations or 
“marks” on the chromosomes that create and perpetuate altered activity states (191). 
Epigenetic changes can dictate the how, when, and where the sequence information 
will be used. This potential to determine functions and probabilities of disease has 
created specialised research fields focusing on possible cause-effect relationships. 
Nutrigenomics in particular focuses on how nutrients affect gene expression. There 
is now a large body of research exploring the influence of nutrition on  methyl and 
acetyl groups that constitute the key epigenetic marks (190).  
 
The intrauterine environment represents the most intense epigenetic activity period 
and thus, maternal diet is likely to have long-lasting effects on the development of 
non-communicable chronic diseases in adult life such as the metabolic syndrome, 
insulin resistance, type 2 diabetes, and obesity (98). 
 
The international research project “Early Nutrition” (http://www.project-
earlynutrition.eu) funded by the European Commission aims to find strategies for 
preventive intervention during early life (192). One of the branches of research in 
this project is focused on specific genes and single nucleotide polymorphisms (SNPs) 
that have been identified by genome-wide association studies and candidate genes 
association studies as being significantly associated with obesity. One of those genes 
is the fat mass and obesity associated (FTO) gene. 
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Genome wide association studies identify variants in the DNA, not genes themselves. 
FTO is a gene of nine exons on chromosome 16 in humans and chromosome 8 in 
mice. The original variant (SNP) associated with BMI and obesity in humans, was 
found in the first intron (rs9939609) (41). More single nucleotide polymorphisms 
were later discovered on the same intron (193), but rs9939609 has been the main 
variant of research interest (194). The risk allele frequency is close to 50% in 
Caucasians and Yorubans (an African ethnic group) and 14% in Asians, so it may 
affect the weight of almost half the world population.  
 
However, it is now suggested that all of the identified SNPs of the same highly 
correlated cluster on introns 1 and 2 are associated with BMI and other 
obesity-related traits at similar significance levels (51). Although we know that FTO 
is an AlkB-like 2-oxoglutarate–dependent nucleic acid demethylase, the exact 
function of the FTO gene in relation to obesity remains elusive. It is not known 
whether there is cause-effect relationship or an interaction between nutrition and 
FTO gene expression (49, 77, 193-197).  
 
Humans homozygous for the ‘obesity-risk’ A allele of FTO rs9939609 have a 1.7-
fold increased risk for obesity compared with subjects homozygous for the low-risk 
T allele, and display overall increased ad libitum food intake, particularly fat 
consumption, and impaired satiety (198). Moreover, preschool AA children show 
obesity-prone eating behaviors, including increased food responsiveness and a 
tendency to eat in response to external cues, prior to the development of an 
association between FTO rs9939609 and BMI. Research to date suggests that the 
association between SNPs in FTO and BMI is predominantly driven by increased 
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energy intake. 
 
The FTO gene is expressed in all fetal and adult tissues but at much higher levels in 
the hypothalamus and in particular in the arcuate nucleus (41, 57).  It is also highly 
expressed in the human placenta (74) and associated with increased fetal weight and 
length. FTO demethylates N6-methyladenosine, a potential regulatory RNA 
modification, but the mechanisms by which FTO predisposes humans to obesity still 
remain unclear (199). These findings suggest that there is likely to be a prenatal 
effect on FTO expression. 
 
One of the first animal studies on the function of FTO investigated its protein 
products and whether these were nutritionally regulated. Three groups of mice 
(freely feeding, fasted 48 h and fasted 48 h with daily injections of leptin) were 
compared. mRNA levels of FTO in the arcuate nucleus were reduced by 60% in 
fasted mice compared with controls and were not influenced by leptin 
supplementation (42). Further research showed that in rats exposed to a high fat diet 
for 10 weeks, FTO gene expression increased 2.5 fold in the arcuate nucleus of the 
hypothalamus (84).  
 
Research around FTO gene is still challenging. The fact that its function is still 
unknown and that the obesity associated variants of this gene are located in an 
intronic area makes it difficult to point the exact mechanism by which this gene is 
implicated in obesity and other metabolic traits associated with non-communicable 
disease. There have been several hypotheses but none is definitive. Many studies 
suggests an association with hypothalamic control of energy intake, leptin and food 
intake, but others indicate a link to adipogenesis or energy expenditure (Figure 3.0) 
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(193). The potential physiological roles and mechanisms of the FTO gene are so vast 
that it is difficult to understand the cause-effect relationship of this gene with obesity 
and related traits. It is clear, however, that FTO expression can be regulated by 
nutrition and its expression may influence other processes in turn (194). 
 
 
Figure 3.0 Putative physiological roles and potential cellular mechanisms of 
FTO. From: Larder et al. 2011 (193), Trends in Endocrinology & Metabolism. 
 
More recently, Karra and colleagues (198) showed that adiposity-matched, normal-
weight  humans who were homozygous for the FTO obesity risk rs9939609 A allele 
had dysregulated circulating levels of the orexigenic hormone ghrelin and attenuated 
postprandial appetite reduction. Using functional magnetic resonance imaging in 
normal-weight AA and TT humans, they found that the FTO genotype modulates the 
neural responses to food images in homeostatic and brain reward regions. The AA 
and TT subjects exhibited divergent neural responsiveness to circulating ghrelin 
within brain regions that regulate appetite, reward processing, and incentive 
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motivation. In cell models, these researchers showed that FTO overexpression 
reduced ghrelin mRNA N6-methyladenosinemethylation, concomitantly increasing 
ghrelin mRNA and peptide levels. Furthermore, blood cells from AA human subjects 
exhibited increased FTO mRNA, reduced ghrelin mRNA N6-methyladenosine 
methylation, and increased ghrelin mRNA abundance compared with TT subjects. 
Together, their findings suggest that FTO regulates ghrelin, a key mediator of 
ingestive behavior, and offer insight into how FTO obesity-risk alleles predispose to 
increased energy intake and obesity in humans. 
 
In one of the earliest nutrigenomic studies, Kallio and colleagues (200) showed that 
two carbohydrate modified diets (i.e. different GI) differentially modulated gene 
expression in abdominal subcutaneous adipose tissue of men and women with the 
metabolic syndrome. The differences were evident even in the absence of changes in 
body weight. Genes involved in insulin signalling were down-regulated during the 
lower GI diet, and genes related to metabolic stress were up-regulated during the 
higher GI diet. This suggested that even a short exposure (12 weeks) could impact 
the risk of metabolic diseases via changes in gene expression. Unfortunately, the 
FTO gene was not studied in that trial. 
 
Nonetheless, Kallio’s findings led us to hypothesise that two iso-energetic and 
nutritionally identical diets differing only in their GI (high vs. low) would evoke 
differential FTO gene expression at its main expression sites (the hypothalamus and 
the placenta). We hypothesised that there would be higher FTO expression and lower 
leptin expression in the high GI diet groups. Our hypothesis is underpinned by 
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previous evidence that FTO gene is involved in the processes of appetite and satiety, 
and with leptin expression.  
 
3.2 Materials and methods 
3.2.1 Study design 
The study design has been described in detail in Chapter 2. Briefly, all animal work 
was approved by the Animal Ethics Committee of the University of Sydney 
(Protocol number L02/8-2010/2/5355). Animals were provided by the Animal 
Resources Centre (Canning Vale, WA). Mice breeders were kept in indoor animal 
house facilities (temperature kept constant at 25
o
 C), where two to six same sex mice 
were housed together in standard cages containing clean paper pellets and paper rolls 
to shred. Mice had ad libitum access to their feed and water through a feeder tray 
within the lid of the cage. The light-dark cycle of the animal holding room was 12 h-
12 h.  
 
Feeds were obtained commercially from Specialty feeds, Glen Forest, WA, Australia. 
The purchased special diets were of the same energy density and all macronutrients 
were matched. The physical and chemical structure of the starch fraction was 
manipulated by the manufacturer in order to obtain a ‘gel crisp’, high amylose starch 
for the low GI diet (LGI: 70% amylose, 30% amylopectin) and a dextrinised, high 
amylopectin starch for the high GI diet (HGI: 90% amylopectin, 10% amylose). Both 
diets were enhanced with AIN93 vitamin premix that used wheat instead of sucrose 
or glucose. 
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A schematic representation of the design of the two studies involved in this chapter 
is shown below.   
 
1
st
 study 
 
2
nd
 study 
 
 
As described in the previous chapter, 4 week old female C57BL/6 mice were 
randomly assigned to one of the following diet groups: low GI diet (LGI), high GI 
diet (HGI) and standard chow (CC). Male breeders (received at 3 weeks of age) were 
all fed a standard chow diet throughout. Their chow regime was interrupted for 
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breeding purposes only. Mice were maintained on their assigned diet for four weeks 
prior to mating. 
 
Mating was based on the “Breeding Strategies for Maintaining Colonies of 
Laboratory Mice” Resource Manual by the Jackson Laboratory 
(http://jaxmice.jax.org/manual/#breeding). At birth only male pups were used for this 
research and female offspring were made available to other researchers. Male pups 
from the LGI and HGI groups were weaned at the end of postnatal week 4 and were 
further divided into two subgroups, one following their mother’s diet (LL and HH 
respectively) and one following the CHOW diet (LC and HC respectively). Male 
pups of the CHOW group were weaned at the same time and continued on CHOW 
(CC). This last group has been used as the group of reference and comparison for our 
analysis. 
 
3.2.2 Ear-marking, food intake and weight monitoring 
At 4 weeks of age, male pups were anaesthetised using isoflurane (ISO) solution 
within a glass chamber.  A surgical scissor was used to obtain one of six unique ear 
punches (three sites for the right and three sites for the left ear). After weaning, the 
pups’ weight was recorded weekly until the age of five months when they would be 
sacrificed. Three 24 h food intake observations were conducted at weeks 9, 12 and 
16. Mice were placed in custom made cages that contain an insert to allow catching 
spilled food. 
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3.2.3 Mouse sacrifice, blood and tissue collection 
Study 1:  
As described in chapter two, mice from all three groups were sacrificed at 20 weeks 
of age, by intraperitoneal injection with 100 µl of Lethabarb euthanasia solution. 
After the injection, mice were observed until death was confirmed by absence of 
respiratory movement and corneal reflex. The following tissues were collected: 
hypothalamus, brown adipose tissue (BAT), liver, visceral adipose tissue (VAT), 
subcutaneous adipose tissue (SAT), red muscle (RM), and white muscle (WM). 
Collected tissues were snap-frozen in liquid nitrogen and stored at  -80
o
C until 
further analysis. 
 
For the collection of the hypothalamus, the brains were free-hand rapidly but 
carefully removed from the skull and placed in the bottom of a glass Petri dish filled 
with 0.1 M sodium phosphate-buffered saline solution. Removal of the 
hypothalamus was conducted by dissecting away the optic chiasm from the anterior 
portion of the hypothalamus and the mammillary nuclei from the posterior of the 
hypothalamus. The entire hypothalamus was removed including the arcuate, 
ventromedial, dorsomedial, and paraventricular nuclei and was quickly separated and 
immedietly snap-frozen in liquid nitrogen. 
 
Study 2: 
Female pregnant mice from the HGI and LGI groups were sacrificed at day 18-19 of 
gestation, close to the end of pregnancy. They were anaesthetised using a lethal dose 
of isoflurane (ISO) solution within a glass chamber. (An interperitoneal injection of 
Lethabarb was not appropriate for the recovery of the placenta (201),(202).) The 
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belly of the mouse was sprayed with ethanol and by a small incision, the skin was 
removed in order to access and open the peritoneum. Successively, the uterine horns 
were picked up at each distal end and placed in a petri dish containing phosphate 
buffered saline (PBS) solution. Figure 3.1a shows a photograph taken during a 
placenta recovery process.  
 
 
Figure 3.1a C57BL/6 pregnant mice and embryos.  
This photo was taken during a sacrifice for the recovery of the placentas. Each 
mouse had very similar appearance, with multiple embryos in their own amniotic sac 
and an individual umbilical artery connecting to the uterine artery. 
 
Each embryo was treated separately in a separate petri dish containing PBS. The 
amniotic sac was opened and the embryo separated from the placenta by a slicing 
incision on the umbilical cord and pulling the cord and the attached embryo away 
from the placenta. The placenta was then snap-frozen in liquid nitrogen and stored at 
-80
o
C until further analysis. 
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3.2.4 RNA extraction 
Total RNA extraction was conducted using RNeasy Lipid Tissue Mini Kit by Qiagen 
for tissues weighing ≥30 mg as per manufacturer’s instructions. For smaller tissues 
such as hypothalamus and placenta, RNA extraction was conducted using RNeasy 
Mini Kit by Qiagen. Briefly, for the first study the following tissues were used for 
purification of total RNA: hypothalamus, brown adipose tissue (BAT), liver, visceral 
adipose tissue (VAT), subcutaneous adipose tissue (SAT), red muscle (RM) and 
white muscle (WM). 
 
Tissue samples were disrupted and homogenised using QIAzol™ lysis reagent. For 
tissues that were larger and more fibrous, the Polytron™ handheld homogeniser was 
used for 10-15 seconds in order to achieve a homogeneous mixture. The resulting 
samples were allowed to stand at room temperature for 5 min after which 200 uL 
chloroform was added. The tissues were then vortexed for 30 sec and left at room 
temperature for 3 min. Tissues were then centrifuged (12,000 g, 15 min, 4 °C) using 
a microcentrifuge (Heraeus Biofuge Fresco™, Thermo Fisher Scientific). The 
supernatant aqueous phase containing RNA was transferred to a new tube where a 
1:1 ratio of 70% ethanol solution was added. This was then transferred into the 
RNeasy column using extraction tubes provided in the Qiagen kit. After 
centrifugation and discard of the flow-through, the column was placed in a new 
Eppendorf rube where RNase-free (DEPC) water was added up to obtain a volume 
of 100 uL of solution. 
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3.2.5 Determination of RNA purity and yield 
The RNA purity and yield were controlled using a NanoDrop (ND-1000) 
spectrophotometer (NanoDropTechnologies Inc, USA) and gel electrophoresis. The 
UV spectrophotometer was blanked with DEPC water and undiluted RNA samples 
(1.5 μL) were analysed. The determination of the yield and the purity of the RNA 
from protein and salt contamination was based on the A260 and A260:A280 and 
A260:A230 ratios. 
 
A denaturing formaldehyde gel electrophoresis was used to determine the integrity 
of the purified RNA samples, using 18S and 28S ribosomal RNA as standard.  
Approximately 2 μg of the RNA sample was mixed with MOPS (20 mM MOPS, 5 
mM NaOAc, 1 mM EDTA, pH 7.0), 20% formaldehyde, 50% (v/v) formamide, and 
0.0125 μg ethidium bromide, obtaining a final volume of 10 μL. Samples were 
heated to 65 °C for 5 min and quickly chilled on ice.  
 
Samples were mixed with 10 x loading buffer (25% (v/v) glycerol, 0.25% (w/v) 
xylem cyanol FF, 10 mM EDTA, pH 8.0), then were loaded onto a 1.5% (w/v) 
agarose gel (containing 1x MOPS, 2.2 M formaldehyde). Electrophoresis was carried 
out at 80 V applied for ~1 h. The agarose gel was then  photographed under UV 
trans-illumination. The samples that showed clear bands with a 2:1 intensity of 
28S:18S ribosomal RNA were determined good quality samples and used in the next 
step of the cDNA synthesis. 
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3.2.6 Synthesis of cDNA and primer design 
Total RNA was reverse transcribed from 200 ng of total RNA in a final reaction 
volume of 20 μL, using Superscript® VILO™ cDNA Synthesis Kit (Life 
Technologies, city) according to manufacturer’s instructions. The mRNA sequences 
of the two target genes (Fto and leptin) were found at http://www.ncbi.nlm.nih.gov/ 
and the primers were designed using the ‘Primer3’ (v. 0.4.0) web tool, which is 
available at http://frodo.wi.mit.edu/primer3/. The search criteria used for choosing 
the correct primers were: primer length optimal at 20 bp, ~50% GC content, close or 
same Tm, amplicon size between 80-120 bp. The primers were not designed using 
intron spanning but they were designed to bridge the exon-intron boundaries within 
the gene of interest to exclude possible contamination by genomic DNA.  
 
Once the pairs of the primers were chosen, the oligonucleotides were synthesised by 
Sigma Genosys (Sigma-Aldrich). The primers were experimentally validated with 
two quality control assays. First, a melt curve analysis, confirmed by agarose gel 
electrophoresis, verified that a single gene-specific product was produced. Each 
sample was run in triplicate. In addition we checked the amplification efficiency 
through a calibration curve. The slope of the Ct values versus the initial amounts of 
input material on a semi-log10 plot (of the best fit line) was calculated and we 
obtained an amplification efficiency > 90 %. 
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The sequences of the oligonucleotides were as follows: 
Oligo name Length Tm
o
 GC% Sequence (5’- 3’) 
Mus_FTO_fwd 20 64.0 60% GTGAGGACGAGTCCAGCTTC 
Mus_FTO_rev 20 64.0 55% AGCAGTCTCCCTGGTGAAGA 
Lep_fwd 20 63.8 45% CTCTTTCCGGAACATTTGGA 
Lep_rev 20 63.7 45% GCTCAGCAATATGCCAACAA 
18s_fwd 20 67.6 60% CACGGCCGGTACAGTGAAAC 
18s_rev 18 66.4 61% AGAGGAGCGAGCGACCAA 
 
3.2.7 Quantitative Real-time PCR (qRT-PCR) 
In PCR the cDNA targeted sequence is amplified using the specific primer pairs. We 
used the Fast SYBR® Green Master Mix (Applied Biosystems) containing Syber 
Green fluorescent dye which binds only double stranded DNA with an intensity 
proportional to the amount of double stranded product formed. The fluorescence 
after each amplification cycle was measured and the number of cycles required to 
achieve a pre-set level of double stranded DNA (threshold) determined. The more 
abundant the sequence in the initial cDNA preparation, the fewer cycles are required 
to achieve the threshold.  
 
We used 96-well plates (Applied Biosystems) with a total reaction volume of 20 μL. 
According to the manufacturer’s instructions, we added 10 μL of Fast SYBR® 
Green Master Mix, 1.5 μL of forward and reverse primers and 7 μL of cDNA sample. 
Each sample was run in duplicate and in 1:1 and 1:8 dilutions. For the 18S ribosomal 
RNA primers which act as an endogenous control, additional 1:64 dilutions were 
conducted. We chose 18S rRNA as an internal control in relative RT-PCR rather 
than ACTB or GAPDH because it shows less variance in expression across a variety 
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of tissues and of treatment conditions than β-actin and GAPDH. Indeed in FTO gene 
analysis specifically, 18S is the dominant internal control (82, 103, 203, 204). 
 
The amplification was performed in an ABI 7500 instrument (Applied Biosystems) 
with two-step thermocycler program. The first 5 min step was a 50 ºC pre-incubation 
to remove contaminating amplified product from previous PCR assays. The second 
step consisted of 40 cycles comprising 3 seconds at 95 ºC then 30 seconds at 60 ºC. 
A melt curve was performed and all the Ct values were normalised to the appropriate 
18S rRNA Ct value which was used as the reference sequence. Levels of 18S did not 
differ between groups. The gene expression was estimated by using the Ct (2ΔΔct) 
method (205). 
 
3.2.8 Data and statistical analysis 
Gene expression is presented as fold change compared to the control group, i.e. the 
chow-fed offspring of chow-fed mothers. Prism 6.0 (Graph Pad Software, USA) and 
SPSS Statistics 19 (IBM) was used for statistical analysis. One-way repeated 
measures analysis of variance (ANOVA) followed by two-tailed unpaired t-tests 
with the Bonferroni adjustment were performed to assess the difference between the 
groups for the expression levels of the two target genes. Due to the large number of 
variables we investigated, a statistical p value of ≤ 0.05 was taken as marginal 
significance and < 0.01 as significantly different.  
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3.3 Results 
Study 1: The expression of the Fto gene varied considerably among the different 
tissues and also between treatment groups. Expression was 8-fold higher in the 
hypothalamus than in the next highest tissue, the red muscle (Figure 3.1b). 
Hypothalamic Fto gene expression was 2.5-fold higher in the HH group than LL 
(Figure 3.2, p = 0.0001) whereas HC and LC were not different (Figure 3.2, p = 0.1). 
The CC group was marginally different to two of the treatment groups: HC (p = 0.03) 
and HH (p = 0.01). 
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Figure 3.1b Fto gene expression across tissues. Data represent mean values ± sem. 
The values were calculated for the control group (CC) and expression of Fto is 
relative to 18S. 
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Figure 3.2 Fto gene expression in the hypothalamus of 20-week male C57BL/6 
mice. Values represent mean expression ± sem. CC n = 7, HC n= 6, LC n = 10, HH 
n = 5, LL n = 6. 
 
In the brown adipose tissue (BAT), there were no significant differences among the 
diet groups (Figure 3.3). 
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Figure 3.3 Fto gene expression in the brown adipose tissue of 20-week male 
C57BL/6 mice. Values represent mean expression ±sem. No significant differences 
(NS) were observed. CC n = 7 , HC n= 7, LC n = 8, HH n = 6, LL n = 7. 
 
Similarly, in the liver tissue, there were no significant differences between HC and 
LC (p = 0.7) or HH and LL (p = 0.8). Fto gene expression in the CC group was 
marginally lower than in HC and LC (p = 0.01) (Figure 3.4). 
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Figure 3.4 Fto gene expression in the liver of 20-week male C57BL/6 mice. 
Values represent mean expression ± sem. CC n = 7, HC n= 7, LC n = 8, HH n = 6, 
LL n = 7.  There were no differences between diets (HC vs. LC, or HH vs. LL) but 
CC lower than in HC and LC (p = 0.01)    
 
In sub-cutaneous adipose tissue, there were no significant differences among any of 
the diet groups (Figure 3.5). In the visceral adipose tissue, however, there was 
significantly lower Fto gene expression in both HH and LL groups compared to the 
CC group (p<0.001, Figure 3.5).  
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Figure 3.5 Fto gene expression in the adipose tissue of 20-week male C57BL/6 
mice. Values represent mean expression ± sem. No significant (NS) differences were 
found in the visceral adipose tissue. VAT: CC n = 7 , HC n= 7, LC n = 6, HH n = 6, 
LL n = 6. SAT: CC n = 7, HC n= 7, LC n = 7, HH n = 5, LL n = 7 . 
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In the white muscle, Fto mRNA expression was nearly 3-fold greater in the LC 
group compared to HC (p = 0.0001) and 1.5-fold higher in LL group vs. HH (p = 
0.0001) (Figure 3.6). The CC group was significantly higher only compared to HC 
(p = 0.001). By contrast, in red muscle, the HC group was 2-fold higher than LC (p = 
0.0001) (Figure 3.6), while CC was higher than the remaining groups (p = 0.001).  
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Figure 3.6 Fto gene expression in the muscle. Values represent mean expression ± 
sem. WM: CC n = 5, HC n= 5, LC n = 4, HH n = 5, LL n = 5. RM: CC n = 5 , HC n= 
7, LC n = 6, HH n = 7, LL n = 4 . 
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Leptin mRNA expression (Figure 3.7 and 3.8) was measured only in adipose tissue, 
since constitutive leptin expression has mainly been demonstrated in this tissue. In 
visceral adipose tissue leptin mRNA expression of the LC group was 4.4-fold higher 
than HC (p = 0.0001) and LL was 3.3-fold higher than HH (p = 0.0001). In 
subcutaneous adipose tissue, there were no significant differences between the 
groups. Even though LL showed a ~3.5–fold higher leptin expression than HH, this 
difference was only marginal because of the small number of animals (Figure 3.7, p 
= 0.02). The difference between LC and HC was not significant.  
 
 
Figure 3.7 Leptin gene expression in the visceral adipose tissue. Values represent 
mean expression ± sem. VAT: CC n = 5, HC n= 6, LC n = 6, HH n = 6, LL n = 6.  
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Figure 3.8 Leptin gene expression in the subcutaneous adipose tissue. Values 
represent mean expression ± sem. CC n = 6, HC n= 7, LC n = 7, HH n = 4, LL n = 4. 
 
Study 2: Placentas were recovered from the high GI (PH) and low GI (PL) mothers 
at 18-19 days gestation. Fto expression was 3.8-fold higher in the high GI-fed 
mothers compared to the low GI mothers (Figure 3.9, p = 0.0001). 
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Figure 3.9 Fto gene expression in the placenta. Values represent mean expression 
± sem. PH, placentas recovered from high GI-fed mothers, n = 15.  PL, placentas 
recovered from low GI-fed mothers, n = 18. 
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3.4 Discussion  
To our knowledge, this is the first study to examine the direct effects of maternal 
high and low GI feeding on Fto and leptin gene expression in offspring.  The 
findings show that Fto gene expression in key tissues is significantly regulated by 
both early-life and life-long exposure to different sources of dietary carbohydrate. 
The most important outcome was the 2.5-fold higher expression of Fto in the 
hypothalamus of pups exposed to a high GI diet vs. low GI diet from conception to 
20 weeks of age (HH vs. LL). In the placentas of high-fed mothers, Fto expression 
was 4-fold higher compared with those fed a high GI diet.  In contrast, there were no 
differences in expression of Fto in offspring liver or the adipose tissues, although 
surprising differences occurred in red and white muscle. There were also important 
differences in leptin gene expression, with 3 to 5-fold higher levels in the low GI fed 
pups compared to high GI fed offspring. Together these findings indicate an 
important role of carbohydrate nutrition and/or postprandial glycaemia in the in utero 
environment on the pattern of gene expression later in life.  
 
The fat mass and obesity (FTO) gene has one of the strongest links with BMI in the 
human population. One in six people have the “risk” alteration and weigh 3 kg more 
than those with the unaltered gene, but it is not understood how this gene influences 
BMI and obesity. We set out to understand whether maternal diet affected offspring 
FTO expression using a mouse model. Although previous rodent studies demonstrate 
a role for FTO in energy homeostasis and body composition, the relationship 
between brain FTO mRNA levels and food intake remains controversial. Specifically, 
it is still unclear whether up-regulation of FTO expression is causal for obesity. 
However, in mice, Church et al. (83) showed that enhanced expression of Fto leads 
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to increased food intake and obesity in a dose-dependent manner. Therefore, in the 
present study, a 2.5-fold greater hypothalamic Fto expression in the pups exposed to 
a high GI diet vs. low GI diet, suggests that a high GI diet leads to greater risk for 
obesity and associated disorders. However, despite these differences in Fto gene 
expression, in the previous chapter we show no differences in food intake between 
the groups. We speculate that this is due to the low fat content of the diets in the 
current study, which probably causes low palatability for both the low and high GI 
feeds. 
 
Although there are no similar studies to ours comparing the effects of maternal 
nutrition on Fto expression in the offspring, our results can be compared with 
findings in older animals fed different diets. Cheung at al. (85) also showed that Fto 
gene expression was down-regulated in mouse hypothalamic cells and embryonic 
fibroblasts deprived of amino acids. Tung et al.(84) reported that in rats exposed to a 
high fat diet, Fto gene expression in the arcuate nucleus of the hypothalamic area 
was up-regulated (2.5-fold) compared to the chow-fed control. In contrast, Gutierrez-
Aguilar et al. (206) reported that Fto gene expression in the hypothalamus was 
down-regulated in rats fed a high fat diet compared to those fed chow. These 
inconsistent findings may be related to the length of exposure to the dietary 
intervention.  
 
The findings of the present study do not support the hypothesis that the glycaemic 
impact of the diet influences Fto gene expression in tissues such as adipose and liver, 
tissues that are specialised for fat synthesis and storage. Indeed, there were no 
important differences between diet groups in relation to brown adipose tissue or sub-
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cutaneous and visceral tissue.  
 
In contrast, there were unexpected differences in red vs. white muscle tissue.  In 
white muscle, Fto expression was significantly higher in both low GI groups (LC 
and LL) compared to their respective high GI groups (HC and HH). By contrast, in 
red muscle, expression was higher in the pups of mothers fed a high GI diet until 
weaning (HC vs. LC) but not between HH vs. LL. These inconsistent findings may 
relate to the different functions of white vs. red muscle. Red muscle (type 1 or slow 
twitch), is dense with capillaries and rich in mitochondria and myoglobin, giving the 
muscle tissue its characteristic colour. It carries more oxygen and can sustain aerobic 
activity using fats or carbohydrates as fuel for longer (207) .  
 
On the other hand, white muscle (type IIb, fast twitch) muscle is anaerobic and 
glycolytic, and is least dense in mitochondria and myoglobin. In small animals such 
as rodents this is the major fast muscle type, explaining the pale color of their flesh. 
It is possible therefore that carbohydrate nutrition during gestation influences the 
expression of genes regulating the fuel mix during prolonged strenuous exercise. In 
humans, low GI meals have been shown to extend endurance performance (208, 209), 
although this may be more related to the acute effects of glycaemia than gene 
expression over the longer term.   
 
Interestingly, in line with our findings in muscle, McMurray et al (76) found that Fto 
appeared to have a critical role in the control of lean mass, independent of its effect 
on food intake. Removing FTO everywhere from conception had a dramatic effect 
on body composition and resulted in stunted growth and some lethality. Removing 
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FTO everywhere but only in adult animals resulted in better viability and normal 
growth but, surprisingly, reduced lean mass and increased fat mass with a change in 
the type of metabolic fuel being used. When they removed FTO from the 
hypothalamus of adult animals, these animals showed only a mild reduction in food 
intake and weight gain. Clearly, further research is needed to elucidate the meaning 
of changes in Fto expression in muscle vs. adipose tissues.  
 
In the present study, we observed 4-fold higher expression of the Fto gene in the 
placentas of the high GI vs. low GI mothers. Placental programming by dietary 
manipulation is not yet widely researched and understood. Adaptations in placental 
phenotype have been observed in response to severely restricted dietary 
manipulations, which lead to a reduction of the nutrient transfer capacity of the 
placenta (104). These researchers showed that in mice, small alterations in the 
protein and carbohydrate content of the gestational diet led to significant differences 
in the expression of placental Igf2 on gestational day 16. Expression of the glucose 
transporter gene Slc2a1 and placental transfer of glucose were also differently 
affected by dietary interventions. Studies conducted in diabetic pregnancies have 
also shown that maternal gestational hyperglycemia may be involved in the 
pathogenesis of IR, impaired glucose tolerance, type 2 diabetes mellitus, the 
Metabolic Syndrome and subsequent cardiovascular diseases in adult offspring. A 
low GI maternal diet rather than a low carbohydrate diet, has been associated with 
measurable benefits to the offspring such as fetal and placental insulin and glucose 
regulation, fetal growth, birth weight and offspring adiposity (131, 133, 210).  The 
differences in Fto gene expression in the placenta observed in the present study 
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suggest that postprandial glycaemia, rather than the dietary carbohydrate content, is 
the mechanism that regulates placental gene expression.  
 
Our study also showed significantly higher expression of the leptin gene in visceral 
adipose tissue of offspring of low GI fed mothers (LC vs. HC and LL vs. HH). This 
can be interpreted in two ways i) as indicative of higher leptin production and 
therefore higher plasma leptin concentration or ii) indicative of greater body fat in 
the low GI fed pups. In humans and animal models, leptin concentration increases 
with higher body fat. Leptin gene expression in white adipose tissue has also been 
shown to be elevated in rats fed a high fat diet compared to a standard diet (211), 
indicating nutritional regulation of this gene. Nonetheless, in Chapter 2, we 
demonstrated that plasma leptin levels were higher in offspring of low GI mothers 
who were phenotypically the same as those of high GI mothers (similar body weight, 
insulin sensitivity and glucose tolerance). We also observed lower levels of the 
orexigenic hormone ghrelin in the low GI fed animals. Although an argument could 
be made regarding the possibility of leptin resistance in the low GI fed animals, as 
well as the fact that we cannot rule out differences in body fat composition, the 
weight of evidence suggests that high leptin gene expression in the low GI fed 
offspring results in higher leptin protein production and therefore greater satiety, and 
over the longer term, a reduced risk of excessive food intake and obesity.   
 
The finding of higher expression of Fto and lower expression of leptin in the high GI 
offspring, in concert with the higher levels of ghrelin and lower levels of leptin in 
plasma (as described in Chapter 2) lead us to the conclusion that maternal diets with 
a high GI (or more specifically faster rate of carbohydrate digestion and absorption) 
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are likely to predispose to higher energy intake and greater risk of obesity in adult 
offspring. The fact that there were no phenotypic differences in the animals at the 
time of study strengthens the assumption that these are primary traits rather than 
secondary to higher body weight or body fat.  
 
The strengths of our study include the study design which allowed us to observe the 
early in-utero impact of the maternal nutrition on the expression of Fto and leptin 
genes in the prenatal tissue, the placenta, and in adult tissues of the offspring. This is 
a valuable tool which brings power to the early programming theory. Furthermore, 
the fact that the treatment diets were identical apart from the source of the 
carbohydrate allows us to separate the effect of quantity of carbohydrate and other 
macronutrients from the quality of carbohydrate.  The in vitro studies described in 
Chapter 2 confirmed that the rate at which glucose from each diet becomes available 
for absorption varied according to their GI. This reinforces the potential that low GI 
carbohydrate foods and diets may have on epigenetic programming and prevention 
of obesity and other non-communicable diseases. 
 
The weakness of our study should be noted. The biggest limitation is the use of a 
mouse model to test our hypotheses. It cannot be assumed that human offspring will 
display similar up-regulation of FTO in response to differences in the GI of maternal 
diet. Mice have evolved along a different evolutionary pathway with different native 
diet to humans. As an alternative, non-human primates could be employed although 
this would be expensive and difficult to undertake with large numbers of animals.  
Likewise, as humans, we consume real foods and mixed meals, and rarely do we 
consume a diet that has been manipulated in GI alone as was the case in the present 
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study. The feeds we used were not purified and so their metabolic impact could be 
directly attributed to their starch content.   
 
In summary, the findings of this research have important implications for the 
intrauterine programming of obesity. The perspective that a specific dietary choice, 
such as high or low GI carbohydrates, can regulate the expression pattern of 
regulatory and nutrient supply genes in key areas such as the hypothalamus, placenta, 
muscle and adipose tissues, suggest that changes in carbohydrate nutrition have 
contributed to our current obesity epidemic. Our findings also imply that a low GI 
diet is promising treatment approach that may substantially reduce the adult risk of 
developing diseases programmed in utero. 
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Chapter 4 
Further findings;  
Changes in expression of appetite genes in hypothalamus 
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Chapter 4  Changes in expression of appetite genes in 
hypothalamus 
 
4.1 Introduction 
In Chapter 3, we showed that leptin gene expression in visceral adipose tissue was 
upregulated by both early-life and life-long exposure to a low GI diet. Additionally, 
plasma leptin levels were 6-fold higher in the low GI pups after extended exposure to 
the diet, whereas plasma ghrelin levels were more than twice as high in the high GI 
pups. These outcomes led us to investigate other genes involved in the regulation of 
energy balance and appetite. This part of the research was carried on in collaboration 
with Seung Gwon Seo, a biochemistry honours student. The data presented below 
were therefore incorporated into his honours thesis (212), but the findings have been 
newly interpreted in the light of other results. 
 
Both leptin and ghrelin have well recognised roles in the regulation of food intake, 
energy balance and body weight (213, 214). Leptin is an important adipose tissue-
derived hormone released into the circulatory system as a feedback on adiposity 
level (215, 216).  Leptin signalling, recognised by the hypothalamic leptin receptors, 
signals satiation and influences the expression and activity of other hypothalamic 
orexigenic and anorexigenic neuropeptides (Figure 4.1). In contrast, ghrelin is a gut-
derived hunger-inducing hormone. Gastric emptiness is the main drive for ghrelin 
expression and associated with increased food intake (217). Interestingly, the 
functional role of ghrelin on food intake is also mediated through the hypothalamus 
(218), where it stimulates the expression of orexigenic neuropeptides and inhibits 
anorexigenic neurons in order to increase appetite.  
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Within the hypothalamus, situated in the arcuate nucleus, there are two neuronal 
populations responsible for the integration and processing of information related to 
energy homeostasis, followed by translation into signals influencing appetite and 
energy expenditure. The neurones containing neuropeptide Y (NPY) and agouti-
related protein (AGRP) are stimulated by ghrelin and inhibited by leptin, with the net 
effect of increasing appetite. In contrast, the neurones containing 
proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript 
(CART) are stimulated by leptin and reduce appetite (219). The two neuronal 
populations act together to finely tune feeding behaviour and energy homeostasis 
(166, 213, 220, 221). 
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Figure 4.1. Interaction of peripheral signal hormones and central appetite 
regulation. Figure adapted from Klok et al. (166).  Leptin, secreted from adipocytes, 
inhibits appetite by promoting co-expression of POMC and CART. Gut-originated 
ghrelin increases appetite by promoting co-expression of AGRP and NPY. (AGRP: 
Agouti-related protein, CART is produced by the CARTPT gene: cocaine-and-
amphetamine-regulated transcript prepropeptide, NPY: Neuropeptide Y and POMC: 
pro-opiomelanocortin). 
 
The central neurological orexigenic (appetite-stimulating) response is executed by 
AGRP and NPY in the arcuate nucleus (213). AGRP is an endogenous antagonist in 
the melanocortin system that controls feeding behaviour and energy homeostasis. 
Mice with AGRP mutations have shown increased obesity, insulin resistance, 
somatic growth and predisposition to tumorigenesis (222). Hypothalamic NPY is co-
expressed with AGRP and its effect on food intake was first discovered after rats 
were injected with NPY directly into the hypothalamus (223). This elicited a strong 
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feeding response; a single injection of NPY rapidly increased appetite and food 
ingestion in a dose-dependent manner. Later, King et al. (224) corroborated the 
orexigenic properties of NPY, by blocking specific NPY receptors with synthetic 
antagonists. The direct injection of antagonists significantly reduced frequency and 
amount of feeding.  
 
POMC also plays an important role in the melanocortin system and regulation of 
energy balance and body weight homeostasis (225). Several studies have shown 
decreased hypothalamic POMC mRNA expression in fasted rodents at the same time 
as orexigenic gene expression is increased (226). POMC mutation in humans has 
been associated with a hyperphagic phenotype (215) and its derivative α-
Melanocyte-Stimulating Hormone (α-MSH) is involved in the appetite regulatory 
pathway (227). 
 
Cocaine and amphetamine-regulated transcript (CART) is an anorectic 
neurotransmitter encoded by the CARTPT gene (CART prepropeptide). It is 
involved in food intake regulation by mediating short-term satiety and interacting 
with leptin (228). Although the mechanism is not yet understood, it appears that 
CART acts at hindbrain and hypothalamic sites to inhibit feeding. 
 
Finally, we were interested in leptin receptor (LEPR), a single transmembrane-
domain-receptor protein that in humans is encoded by the LEPR gene (229).  LEPR 
functions as a receptor for the adipocyte-specific hormone leptin in the 
hypothalamus. Variations in the leptin receptor have been associated with obesity. In 
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the db/db mouse model of obesity and diabetes, for example, leptin receptor activity 
is deficient because the mice are homozygous for a point mutation in the LEPR (230).  
 
The aim of these further investigations was to determine whether there were 
differences in the expression of hypothalamic appetite-regulating genes (AGRP, 
NPY, POMC, CART and LEPR) as a result of early-life and life-long exposure to a 
high vs. low GI diet.  
 
Our hypotheses were: 
1. High GI diet offspring will show higher hypothalamic expression of 
orexigenic AGRP and NPY 
2. High GI diet offspring will show lower hypothalamic expression of 
anorexigenic POMC and CART 
3. High GI diet offspring will show lower hypothalamic expression of leptin 
receptor gene, LEPR 
4. Any adverse effects of early-life exposure to a high GI diet will be 
exacerbated by life-long exposure  
  
4.2 Materials and methods 
4.2.1 RNA extraction and primer design 
As described in detail in Chapter 3, total RNA extraction from the whole 
hypothalamus was conducted using RNeasy Mini Kit by Qiagen as per 
manufacturer’s instructions. The RNA purity and yield were controlled using a 
NanoDrop (ND-1000) spectrophotometer (NanoDropTechnologies Inc, USA) and 
gel electrophoresis. For the cDNA synthesis, the sets of primers were designed using 
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the ‘Primer3’ (v 0.4) web tool, which is available at http://frodo.wi.mit.edu/primer3/. 
The search criteria were: primer length between 19-23 nucleotides long, amplicon 
optimal size 100 bp, melting temperature (Tm) between 58-62°C with Tm difference 
between primers not greater than 2°C, GC content of primers between 50-55% and 
no 3’ complementarity. The primers were not designed using intron spanning but 
they were designed to bridge the exon-intron boundaries within the gene of interest 
to exclude possible contamination by genomic DNA. Once the pairs of the primers 
were chosen, the oligonucleotides were synthesised by Sigma Genosys (Sigma-
Aldrich). They were experimentally validated with two quality control assays. First, 
a melt curve analysis, confirmed by agarose gel electrophoresis, verified that a single 
gene-specific product was produced. Each sample was run in triplicate. In addition 
we checked the amplification efficiency through a calibration curve. The slope of the 
Ct values versus the initial amounts of input material on a semi-log10 plot (of the 
best fit line) was calculated and we obtained an amplification efficiency > 90 %. 
 
Primers for the target genes, AGRP, NPY, POMC, CART and LEPR were selected 
as follows:  
Oligo name Sequence (5’- 3’) 
Mus_AgrpRP_fwd GGC CTC AAG AAG ACA ACT GC 
Mus_Agrp_rev GAC TCG TGC AGC CTT ACA CA 
Mus_Npy_fwd AGA GAT CCA GCC CTG AGA CA 
Mus_Npy_rev GAT GAG GGT GGA AAC TTG GA 
Mus_Pomc_fwd ACG TGG AAG ATG CCG AGA TTC 
Mus_Pomc_rev GCA CCA GCT CCA CAC ATC TAT 
Mus_Cartpt_fwd TAC TGC TAC CTT TGC TGG GTG 
Mus_Cartpt_rev TTC GAT CAG CTC CTT CTC GTG 
Mus_Lepr_fwd TCT GGA GCC TGA ACC CAT TTC 
Mus_Lepr_rev AGG GTC TGG TGT GGT CAA AAG 
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4.2.2 Quantitative Real-time PCR (qRT-PCR) 
As described in Chapter 3, in PCR the cDNA targeted sequence is amplified using 
the specific primer pairs. We used the Fast SYBR® Green Master Mix (Applied 
Biosystems) containing Syber Green fluorescent dye which binds only double 
stranded DNA with an intensity proportional to the amount of double stranded 
product formed. The fluorescence after each amplification cycle was measured and 
the number of cycles required to achieve a pre-set level of double stranded DNA 
(threshold) determined. The more abundant the sequence in the initial cDNA 
preparation, the fewer cycles required to achieve the threshold. All the Ct values 
were normalised to the appropriate 18S rRNA Ct value which was used as the 
reference sequence. Levels of 18S did not differ between groups. Ct value which was 
used as the reference sequence. Gene expression was estimated using the Ct (2ΔΔct) 
method (205). 
 
4.2.3 Data and statistical analysis 
Gene expression is presented as fold-change compared to the control group, i.e. the 
chow-fed offspring of chow-fed mothers. Prism 6.0 (Graph Pad Software, USA) and 
SPSS Statistics 19 (IBM) was used for statistical analysis. One-way repeated 
measures analysis of variance (ANOVA) followed by two-tailed unpaired t-tests 
with the Bonferroni adjustment were performed to assess the difference between the 
groups for the expression levels of the target genes. Due to the number of variables 
we investigated in this part of the project, a statistical p value of ≤ 0.05 was taken as 
marginal significance and < 0.01 as significantly different. 
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4.3 Results 
Overall, the high GI diet offspring expressed significantly more orexigenic genes 
than the low GI diet mice (LC and LL) and the chow group (Figure 4.2). AGRP 
mRNA expression level was approximately 2.5-fold higher in HC compared to the 
LC group (p = 0.0001). In the offspring exposed to a high GI diet for the entire 20 
weeks (HH), AGRP expression was 1.9-fold higher compared to the LL group, but 
was not statistically significant (p = 0.2). 
 
Hypothalamic NPY mRNA expression level also varied markedly between diet 
groups. As shown in the Figure 4.3, NPY mRNA expression was 3.1-fold higher in 
HH vs. LL. However, this difference was only marginally significant (p = 0.04). The 
difference between HC vs. LC did not reach statistical significance, and both were 
similar to CC (p = 0.1). 
 
POMC gene expression (reflecting appetite inhibition) was significantly higher in 
HC vs. LC (p = 0.004), but there were no differences between HH, LL and CC 
(Figure 4.4). Similarly, CART mRNA gene expression in pups exposed to a high GI 
diet during early life (HC) had significantly higher expression than those exposed to 
low GI feeding (LC) (p = 0.003). In contrast, CART mRNA expression level among 
HH, LL, and CC groups was similar (Figure 4.5). 
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Figure 4.2 AGRP gene expression in the hypothalamus of 20-week male 
C57BL/6 mice. Values represent mean expression ± sem. CC n = 11, HC n= 7, LC n 
= 10, HH n = 7, LL n = 7. 
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Figure 4.3 NPY gene expression in the hypothalamus of 20-week male C57BL/6 
mice. Values represent mean expression ± sem. CC n = 11, HC n= 7, LC n = 11, HH 
n = 9, LL n = 7. 
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Figure 4.4 POMC gene expression in the hypothalamus of 20-week male 
C57BL/6 mice. Values represent mean expression ± sem. CC n = 11, HC n= 6, LC n 
= 11, HH n = 9, LL n = 7. 
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Figure 4.5 CART gene expression in the hypothalamus of 20-week male 
C57BL/6 mice. Values represent mean expression ± sem. CC n = 6, HC n= 7, LC n 
= 11, HH n = 9, LL n = 7. 
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Figure 4.6 LEPR gene expression in the hypothalamus of 20-week male 
C57BL/6 mice. Values represent mean expression ± sem. CC n = 11, HC n= 7, LC n 
= 11, HH n = 9, LL n = 7. 
 
LEPR mRNA expression was up-regulated in both HH and HC groups compared to 
CC. The difference between HC and LC was statistically significant (p = 0.001) but 
the difference between HH and LL was not (Figure 4.6) 
 
4.4 Discussion 
Our findings indicate that the offspring of high vs. low GI mothers display important 
differences in expression of key hypothalamic appetite-regulating genes. Pups 
exposed to a high GI diet throughout fetal and early post-natal life had 2.5-fold 
higher expression of the orexigenic gene AGRP (HC vs. LC, p = 0.0001) while those 
exposed life-long had 3-fold higher expression of the orexigenic NPY gene (HH vs. 
LL, p = 0.04).  Paradoxically, however, expression of the two anorexigenic genes 
(POMC and CART) was also significantly higher in the HC group compared to LC 
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(p = 0.004 and p = 0.003 respectively). Similarly, LEPR gene expression was 2-fold 
higher in HC vs. LC (p = 0.001). Taken together, the findings imply that the source 
of carbohydrate has important epigenetic or programming effects on the developing 
hypothalamus, but the net result on appetite and energy balance is difficult to predict.  
 
The finding of up-regulation of NPY and AGRP in the high GI offspring suggests 
they are more likely to be hyperphagic and show impaired energy intake regulation. 
However, as shown in Chapter 2, food intake, weight gain and body weight up to 20 
weeks of age were similar between the treatment groups.  The lack of difference in 
food intake may not be surprising in light of the significant up-regulated expression 
of the two anorexigenic genes, POMC and CART in high GI offspring (HC vs. LC).  
Early studies unrelated to dietary GI have reported that hyperglycaemia with 
hyperinsulinaemia is associated with enhanced satiety (231). Hence, increased 
glucose concentration along with a neurological gluco-sensing mechanism has the 
potential to up-regulate anorexigenic hormones such as POMC and CART, and 
therefore signal satiation. Thus in the context of the present findings, the 
simultaneous up-regulation of both anorexigenic and orexigenic genes may be a 
normal feedback, homeostatic response to ensure energy balance in a young growing 
animal.  
 
Nonetheless, high GI-fed offspring may be predisposed to over-eating and persistent 
positive energy balance over the longer term.  This is suggested by the fact that the 
absolute difference in orexigenic gene expression between high vs. low GI groups is 
larger (2.5 to 3-fold difference) than that of the anorexigenic genes (less than 2-fold). 
Additionally, the observed up-regulation of the hypothalamic leptin receptor gene 
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(LEPR) in early life high GI-fed offspring (HC vs. LC, p = 0.001) could imply 
reduced satiation through deficient leptin action in the hypothalamus. This 
interpretation is consistent with much lower concentrations of leptin in plasma 
(Chapter 2) and leptin gene expression (Chapter 3) in high GI-fed offspring, but 
contrary to our original hypothesis.   
 
Previous animal studies have documented differences in the effect of the dietary GI 
on the phenotypic outcomes such as body weight and food intake. In rats, it was 
shown that the GI had an independent effect on body composition (135). Pair-
feeding experiments showed that the high GI rats gained the same weight as the low 
GI group even though they consumed less food from week 8 onwards. The authors 
suggested it could be due to lower resting energy expenditure or activity due to 
decreased lean body mass. The study also included an experiment in the obesity-
prone C57BL/6J mice. On a high GI diet, these mice had lower lean body mass and 
nearly twice the body fat compared to the low GI-fed mice with the same mean body 
weight. However, in this study the lower circulating leptin levels could suggest that 
fat mass might actually be lower in mice exposed to a high GI diet from conception 
to adulthood and thus more studies in this area are needed. 
 
Scribner et al. investigated the long-term effects of dietary GI on adiposity and 
energy metabolism in mice. The diets were matched for macro and micronutrients up 
to the age of 40 weeks (136). The high GI mice had lower fat oxidation, 40% greater 
adiposity and were more insulin resistant. Interestingly, these effects were 
independent of energy intake since that was the same between the two diet groups. 
Similarly, a study in 16 weeks old mice (137) showed that the high GI-fed group had 
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significantly higher body weight and increased fat mass. Lastly, Scribner’s group 
conducted a later experiment to investigate the short (6 weeks) and long term (20 
weeks) effects of high versus low GI diets on body composition, liver fat, glucose 
clearance and lipid metabolism in mice (136, 138). All high GI-fed animals showed 
a significant increase in body fat mass and greater liver fat. 
 
Human studies have also reported that a low GI meal or diet is associated with 
enhanced satiety and inhibition of appetite (232-234). Many of these investigations 
were designed as single meal tests (234, 235) and satiety was often assessed 
subjectively (236).  Despite these shortcomings, a recent meta-analysis of GI and 
energy intake indicated that children consuming a high GI diet have consistently 
increased food intake, irrespective of BMI (237). It is therefore plausible to suggest 
that the animals in the present study may be obesity-resistant, or alternatively, too 
young at 20 weeks of age to display differences in food intake and phenotype. It is 
possible that longer exposure to the diets would have produced results similar to 
those found in literature (234). 
 
We also hypothesised that prolonged vs. early exposure to a high GI diet may be 
associated with exaggerated impact on appetite regulating gene expression.  This 
appeared to be true for the NPY gene, and to less extent, the LEPR gene.  But in the 
case of AGRP mRNA, the highest level of expression was found in HC rather than 
HH, suggesting pre-natal exposure to the high GI diet is the major determinant. In 
the case of POMC and CART expression, longer exposure may have even reversed 
some of the effects of early exposure, but experiments with larger numbers of 
animals are required to test this hypothesis. On the whole, it is evident that appetite 
- 142 - 
 
regulating gene expression is dependent on timing of exposure rather than length of 
exposure. It is also probable that a stronger metabolic challenge, such as access to a 
high-fat “western” diet may be necessary to provoke measurable outcomes and 
unmask the phenotypic characteristics of the animals in this timeframe. 
 
The strengths of this study include the fact that it was adequately powered with a 
relatively large number of animals in each group (up to 11 in many cases).  The 
effect on gene expression is also remarkedly consistent, the high-GI fed offspring 
being the group with highest expression. Our conclusions are strengthened by the 
fact that there are no phenotypic differences at this stage, suggesting that differences 
in gene expression are primary rather than secondary to differences in body 
composition, insulin resistance or impaired glucose tolerance. However, a possible 
drawback could be considered the use of whole hypothalamus instead of just the 
arcuate nucleus (ARC) of the hypothalamus, where NPY, AgRP and the other 
neuropeptides are more highly expressed and differ from the rest of the hypothalamic 
regions. 
 
This study provides insight into how a high GI diet increases the risk of obesity and 
other metabolic disorders. Previous studies have demonstrated that epigenetic 
modifications are responsible for altering the expression of key appetite regulating 
genes, including those studied in this chapter: NPY (238), POMC (239) and leptin 
(240). The field of epigenetics has become a subject of special interest in recent 
years because it provides a mechanism for explaining how perinatal nutrition 
becomes a determinant of later health outcomes (99). An epigenetic approach to 
obesity and associated metabolic disorders indicates that nutrition in early life is just 
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as important as an inherited predisposition in determining differences in BMI among 
individuals (241).   
 
To our best knowledge, this is the first study to measure hypothalamic appetite-
regulating gene expression in offspring of high vs. low GI mothers. We show that 
the well recognised co-expression of AGRP/NPY and POMC/CART is regulated by 
the nature of the dietary carbohydrates.  Our novel findings provide molecular 
insights into how differences in carbohydrate nutrition, including rate of digestion 
and/or maternal post-prandial hyperglycaemia provoke differences in the regulation 
of orexigenic and anorexigenic genes in the hypothalamus.  
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Chapter 5   
Investigating the effect of early-life and life-long exposure 
to a high vs. low GI diet on liver histology 
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Chapter 5 Study design and rationale 
 
5.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a group of chronic liver disorders, 
whose clinical manifestation can range from simple fatty deposits (hepatic steatosis) 
to much more marked fat accumulation in the hepatocytes combined with tissue 
degeneration,  and lobular inflammation called non-alcoholic steatohepatitis (NASH). 
In this case the fat accumulation triggers an inflammatory response that leads to liver 
steatohepatitis and fibrosis (242).  
 
NASH is associated with obesity, diabetes, insulin resistance (IR), and 
hypertriglyceridemia. In children, statistics show that NASH may be present in the 
prepubertal age group, particularly in males who are overweight or obese, even 
though clinical signs are rarely shown at such early age (243, 244). Liver biopsy is 
considered the gold standard in establishing the diagnosis, while slow, consistent 
weight loss has been shown to be the most effective treatment for NAFLD.  A low 
glycaemic index diet has been shown to be effective in lowering BMI and this 
dietary treatment is commonly recommended for NAFLD (244). 
 
Hyperinsulinaemia and hepatic insulin resistance are considered to be part of the 
metabolic profile of a patient diagnosed with NAFLD, but the mechanisms and 
pathways involved are still uncertain (245). Indeed, NAFLD is acknowledged as the 
hepatic manifestation of insulin resistance and the metabolic syndrome (246), with 
oxidative stress identified as the most plausible mechanism (247). Patients with 
NAFLD demonstrate decreased levels of antioxidants (245), a fact that enforces the 
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theory behind oxidative stress. Genetic influences are also recognised as having an 
important but still unclear role in development.  
Exposure in-utero and later in life to several dietary factors and especially to 
macronutrients such as carbohydrates can directly influence the development and 
progression of NAFLD (248, 249). Indeed, an increased consumption of simple 
carbohydrates is considered one of the dietary risk factors for NAFLD (249, 250). 
High GI foods have been associated with increased hepatic fat in both rodents and 
humans, and simple carbohydrates, such as fructose, have been shown to lead to 
increased fat deposition in the liver by stimulating hepatic de-novo lipogenesis and 
decreasing lipid oxidation (250). 
 
Little is known about the relationship between the FTO gene, insulin resistance and 
the clinical signs of NAFLD. FTO is not only expressed in the hypothalamus but 
also in almost every tissue related to metabolic disease, including the liver. In the 
past six years, there have been several animal studies that demonstrate a positive 
association between the FTO gene and lipid accumulation in the liver (251). 
Likewise, a recent human study showed that FTO overexpression increased the rate 
of lipogenesis and oxidative stress in myotubes (252). Although oxidative stress is 
thought to play a major role in the NAFLD lipid accumulation (253), the function of 
FTO remains elusive. 
 
Guo et al. (251) explored changes in FTO expression in the liver of rats with 
NAFLD induced by high fat feeding. FTO gene expression was up-regulated along 
with increased oxidative stress. When they conducted in vitro overexpression 
experiments in human hepatocyte cells, they found that overexpression of the FTO 
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gene increased oxidative stress levels and was associated with greater lipid 
accumulation, which led to the conclusion that FTO activated the oxidative stress 
process and disrupted lipid metabolism. 
 
The system for grading or staging fibrosis and steatosis of the liver was first 
developed in 1999 by Brunt et al. (254). Grading was based on a review of liver 
biopsies of adult patients with NASH and the terms mild, moderate, and severe were 
used to indicate the severity of the observed histological lesions. In 2005, an updated 
and validated scoring system was established to evaluate the whole spectrum of 
NAFLD that had improved features of  inter-rater reproducibility and was used for 
both adults and children with any degree of NAFLD (246).  
 
The full range of clinical manifestations of NAFLD observed in humans has not 
been totally replicated in animals. However, animal models are used in verifying 
hypotheses on the pathogenesis of NASH and in performing interventional studies 
(255). The same scoring system can be used for these purposes. 
 
The aims of this part of the study were to observe and study any possible clinical 
signs of abnormal liver histology in mice fed chow versus the early life and life-long 
fed low GI and high GI diet groups. In the case of significant histological findings, 
we considered whether these could be correlated with Fto gene expression levels in 
the liver tissues of the different diet groups. Because higher postprandial 
glycaemia/insulinaemia encourages greater glycogen synthesis, we also endeavoured 
to quantify differences in glycogen deposition in the different treatment groups. 
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5.2 Materials and methods 
5.2.1 Tissue collection 
As described in Chapter 2, liver tissues were collected at 20 weeks of age from all 
five groups: CC, HC, HH, LC, LL. Liver tissue samples were fixed in 4% (w/v) 
phosphate-buffered paraformaldehyde for 48 hours at 4
o
C and then transferred to 
phosphate-buffered saline solution. Subsequently tissues were embedded in paraffin 
and sectioned to allow for histological assessment.  
 
5.2.2 Tissue staining and analysis 
The stains and histological specimens described below were analysed and interpreted 
under the guidance of Clinical Professor James Kench, at the Central Clinical School 
of Pathology, Royal Prince Alfred Hospital, University of Sydney, NSW (Australia). 
The interpretation of the histological results was based on the NASH scoring system 
as by Brunt (254) and Kleiner et al. (246). 
 
The histological stains used in this study included Haematoxylin and Eosin (H&E), 
Milligan's Trichrome Method for connective tissue and Periodic Acid Schiff's (PAS) 
method for carbohydrates (or basement membrane). Haematoxylin and Eosin (H&E) 
is the most widely used staining procedure, involving a two-step process that uses 
hematoxylin solutions for nuclear staining and eosin solutions for cytoplasmic 
staining. 
 
Liver sections were deparaffinised in two changes of xylene (10 min each) and 
hydrated through graded alcohols to water. Subsequently, tissues were stained in 
Harris's haematoxylin for 3 min and washed with water. Excess stains were removed 
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by 10 rapid dips in acid alcohol, followed by blue staining in Scott's Tap Water 
solution for 30 seconds. In this step the nuclei stain blue and cytoplasm remains 
unstained as confirmed under microscope.  
 
For the second step, tissues were placed in 70% ethanol for 30 seconds and 
counterstained in Eosin (two changes 40 seconds each). Graded alcohols were used 
to dehydrate the samples by immersing the entire rack. Samples were then cleared in 
two changes of Xylene (2 min each) and mounted with DPX. In this process, 
cytoplasm, collagen, keratin and erythrocytes are stained pink to red. H&E staining 
allows an overview of the structure of the tissue which enables classification of the 
structures examined as normal, inflamed or pathological. 
 
Milligan's trichrome method for connective tissue is a differential stain that colours 
collagen blue against a red background of hepatocytes and other structures. It stains 
the collagen present in the portal tracts and vessel walls, but also highlights the 
presence and distribution of reactive fibrosis as a result of liver injury, such as 
steatohepatitis.  
 
Sections were stained in Weigert's haematoxylin for 5 min and passed into water and 
blue in Scott's solution. Sections were placed in the following order in these 
solutions: mordant solution for 7 min, 0.1% acid fuchsin solution for 8 min, 1% 
phosphomolybdic acid solution for 3 min, 2% orange G solution for 10 min, 1% 
acetic acid solution for 2 min, 1% fast green solution for 10 min and 1% acetic acid 
solution for 3 min. Subsequently sections were dehydrated using 95% alcohol. After 
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these stains, nuclei and muscle appear magenta, collagen appears green and red 
blood cells appear orange to orange-red. 
 
Periodic Acid Schiff's (PAS) method for carbohydrates was used to identify 
glycogen deposition. This is the most widely used technique in carbohydrate histo-
chemistry and is positive for structures containing neutral sugars.  Sections were 
deparaffinised and hydrated to distilled water and placed in 1% periodic acid 
solution for 15 min in order to oxidise glycol groups to aldehydes. Schiff's working 
solution was used (1:3 dilution for glycogen, fungi and carbohydrate) to create a 
stable product with the aldehydes. Sections were stained with haematoxylin for 3 
min followed by 10 rapid dips in acid alcohol. Samples were placed in Scott’s 
Bluing Solution for 30 sec and dehydrated from 95% alcohol. Glycogen, 
mucopolysaccharide, fungi and basement membrane should stain pink, nuclei blue 
and other tissues remain colourless. 
 
5.2.3 Statistical analysis 
The data were analysed using Prism 6.0 (Graph Pad Software, USA) and IBM SPSS 
Statistics 19. P values were determined by Fisher’s exact test for categorical 
variables and Wilcoxon rank sum test for continuous variables. Odds ratios (ORs) 
and 95% confidence intervals were determined from multiple ordinal logistic 
regression analysis.  
 
5.3 Results 
Results rated by the NASH scoring system (246) are shown in Table 5.1. Successful 
stains were obtained from all treatment groups with the following liver sample 
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numbers:  CC n = 6, HH n = 9, HC n = 5, LC n = 7 and LL n = 4. Average total liver 
weights were 1.2 g and did not vary significantly among the groups (p = 0.4). 
 
Glycogen deposition 
Glycogen was semi-quantitatively assessed either as 0 (no staining on PAS sections), 
1 (focal or diffuse, pale (low intensity) PAS staining), 2 (diffuse moderate staining or 
focal strong intensity PAS staining) or 3 (diffuse strong staining). Figure 5.1 shows 
an example of liver sample for each score. No significant differences were observed 
between the groups (p = 0.481). However, there was a notable difference in the 
frequency of score 3 with CC and HC, indicative of strong glycogen deposition 
(33%). In group LL half of the samples showed focal low intensity stains indicating 
minimum glycogen deposition, whereas only 25% showed diffuse moderate stains, 
the maximum score given to this group. None of the LL samples indicated strong 
glycogen deposition. In contrast, 40% of the HH samples displayed diffuse moderate 
stains and another 40% scored the highest grade 3 (diffuse strong staining), 
indicating a more severe glycogen deposition in this group. Because of the small 
number of samples within each group, there was no overall statistical significance in 
glycogen deposition among the treatment groups. 
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Figure 5.1 Various grades of glycogen deposition. On the left, original 
magnification is 40x. On the right, the same sample is shown with original 
magnification 200x. (A) shows staining grade = 0, (B) shows staining grade = 1, (C) 
shows staining grade = 2 and (D) shows staining grade = 3. 
A 
B 
C 
D 
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Item Score CC HC LC HH LL p value 
HC/LC      HH/LL 
 
Glycogen 
      
0.481 
no staining 0 0 2 (22.2%) 2 (28.6%) 0 1 (25.0%)  
0.890     0.571 
focal or diffuse pale staining 1 2 (33.3%) 1 (11.1%) 0 1 (20.0%) 2 (50.0%) 
diffuse moderate or focal 
strong staining 
2 2 (33.3%) 3 (33.3%) 4 (57.1%) 2 (40.0%) 1 (25.0%) 
diffuse strong staining 3 2 (33.3%) 3 (33.3%) 1 (14.3%) 2 (40.0%) 0 
 
Lobular necrosis 
       
0.976 
None  0 4 (44.4%) 0 1 (20.0%) 1 (25.0%)  
0.045     0.810 
 mild focal necrosis  0 1 (11.1%) 5 (71.4%) 1 (20.0%) 1 (25.0%) 
 scanty focal necrosis  3 (50%) 3 (33.3%) 2 (28.6%) 1 (20.0%) 2 (50.0%) 
Moderate necrosis  3 (50%) 0 0 2 (40.0%) 0 
 marked focal necrosis  0 1 (11.1%) 0 0 0 
 
Ballooning 
      
0.372 
None 0 4 (80%) 7 (77.8%) 3 (42.9%) 2 (40.0%) 3 (75.0%)  
0.182 1.00 
few ballooned cells 1 2 (20%) 2 (22.2%) 4 (57.1%) 2 (40.0%) 1 (25.0%) 
many cells /prominent 
ballooning 
2 0 0 0 1 (20.0%) 0 
 
Lobular inflammation 
       
0.394 
none or <1 focus/field (20x) 0 3 (50%) 7 (77.8%) 2 (28.6%) 2 (40.0%) 3 (75.0%)  
0.069     0.167 
<2 foci/field 1 3 (50%) 1 (11.1%) 4 (57.1%) 0 1 (25.0%) 
 2 – 4 loci/field 2 0 0 1 (14.3%) 3 (60.0%) 0 
 >4 loci/field 3 0 1 (11.1%) 0 0 0 
 
Portal track inflammation 
       
0.828 
None 0 6 (100%) 8 (88.9%) 6 (85.7%) 4 (80.0%) 3 (75.0%)  
0.700 1.00 
Mild 1 0 0 1 (14.3%) 0 1 (25.0%) 
Moderate 2 0 1 (11.1%) 0 1 (20.0%) 0 
 
Microvesicular steatosis 
       
0.260 
none or <10% cells with few 
tiny vacuoles 
0 2 (33.3%) 7 (77.8%) 4 (57.1%) 4 (80.0%) 2 (50.0%)  
0.342     0.683 
few tiny vacuoles in 10-33% 
cells 
1 2 (33.3%) 2 (22.2%) 1 (14.3%) 1 (20.0%) 1 (25.0%) 
few tiny vacuoles in >34% cells 2 2 (33.3%) 0 2 (28.6%) 0 1 (25.0%) 
 
Table 5.1 Baseline histologic characteristics by diet group. Data show the number 
of samples observed for each score/code (and % of total number of samples). C = 6, 
HC n = 9, LC n = 7, HH n = 5, LL n = 4. P values were calculated using the Fisher’s 
exact test.
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Lobular necrosis 
There was marginally significant evidence of increased necrosis in the liver lobules 
of group HC vs. LC (11.1% versus 0% had marked focal necrosis respectively, p = 
0.045), but no difference between HH vs. LL (p = 0.810). Nonetheless, there was a 
trend for the group LL to show none to scanty focal necrosis, whereas 40% of the 
HH group showed signs of moderate lobular necrosis. CC samples were evenly 
distributed between scanty focal to moderate necrosis. 
 
Hepatocyte ballooning 
While hepatocyte ballooning is difficult to reproducibly recognise and grade when 
mild as in our case, a score of 0 (none), 1 (a few ballooned cells) or 2 (many 
cells/prominent ballooning) was subjectively assigned. Overall, there were no 
significant differences between any of the groups.  
 
Lobular inflammation 
Lobular (also known as intra-acinar) inflammation was quantified as 0 (none or <1 
focus/field), 1 (< 2 foci/field), 2 (2-4 foci/field) or 3 (>4 foci/field). The lobular 
inflammatory infiltrate observed in some cases, consisted almost entirely of 
lymphocytes, with a few neutrophils observed occasionally.  However, no findings 
were statistically significant. 
 
Portal tract inflammation 
Portal tract inflammation was assessed as none, mild, moderate or heavy/severe. The 
portal inflammatory infiltrate consisted of lymphocytes. Again no significant 
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histologic findings were observed (p > 0.700), although interestingly only groups HC 
and HH showed signs of moderate portal inflammation.  
 
Fibrosis and steatosis 
There was no evidence of significant fibrosis (defined according to Brunt 1999 and 
Kleiner 2005 (246, 254)), and no architectural distortion. Likewise, macrovesicular 
steatosis, defined as cytoplasmic vacuole or vacuoles as large as or larger than the 
nucleus, was not detected in any of the samples. However, microvesicular steatosis 
was evident. Although it is difficult to grade microvesicular steatosis using light 
microscopy, the following grading system was applied: 0 (none or <10% cells with a 
few tiny vacuoles), 1(a few tiny vacuoles/cell in 10-33% cells), 2 (a few tiny 
vacuoles in >34% cells) and 3 (numerous tiny vacuoles/cell in >34% cells). Figure 
5.2 illustrates an example for each grade. Some samples from the CC, LC and LL 
groups scored 2, indicating few tiny vacuoles/cell in >34% cells.  None of the 
differences reached significance compared to the other groups. 
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Figure 5.2 Scoring of microvesicular steatosis. On the left, original magnification 
is 40x. On the right, the same sample with original magnification 200x. (A) shows 
score = 0, (B) shows score = 1 and  (C) shows score = 2. Score 3 was not observed in 
any of the histological samples. 
 
5.4 Discussion 
In the present study, there were no significant differences in the liver histological 
findings between the high GI and the low GI pups at 20 weeks of age.  Thus there is 
no support for our hypothesis that a high GI diet consumed in pregnancy or beyond 
A 
B 
C 
- 157 - 
 
increases the risk of liver pathology in the offspring. However, some findings 
suggest there is a need for further research with a greater number of animals and at a 
later time in the life 
 
Non-alcoholic fatty liver disease (NAFLD) is an acquired metabolic stress-related 
liver disease with histological manifestations ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (249). 
Carbohydrates in the diet could play a key role in the development and progression 
of NAFLD. In particular, a high consumption of sucrose, fructose and/or high GI 
carbohydrates (a source of rapidly digested and absorbed glucose) has been 
identified as a risk factor, whereas dietary fibre and low GI foods have been 
recognised as protective factors against NAFLD (249).  
 
In animal studies, high fat, western-style maternal diets have been associated with 
epigenetic changes during early development and liver changes similar to NAFLD 
(256). Prenatal caffeine exposure has also been shown to increase the risk of NAFLD 
through effects on intrauterine glucose and alterations in lipid metabolism (248). 
These changes were associated with increased foetal hepatic lipogenesis and reduced 
lipid output in utero, effects that reappeared in later life and aggravated the risk for 
NAFLD.  At the present time, however, there is no direct evidence of epigenetic 
effects of carbohydrates in the maternal diet.  
 
Here we investigated the role that the GI of the maternal and offspring diet might 
play in the development of NAFLD. Although there were some interesting trends, 
none of the differences reached statistical significance. This was the case in relation 
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to glycogen deposition as well as signs of inflammation, ballooning, necrosis or 
steatosis. Pups exposed to the treatment diets either in utero or also later in life did 
not show significantly altered liver histological findings that could indicate a major 
or lesser predisposition to NASH and NAFLD. For this reason, no correlations could 
be made with the earlier finding of differences in gene expression. 
 
The outcomes of this study contrast with findings of a recent study in a multi-ethnic 
cohort of children, all with hepatic steatosis. In this instance, children whose diets 
were higher in foods containing fructose (soft drinks, fruit juice) or high GI and GL, 
had higher risk of NAFLD (257). Interestingly, all children were overweight or 
obese in contrast to our animal model, where the pups in all five diet groups were of 
normal weight.  Thus the physical effects of carbohydrate quality on the liver may 
not be evident unless body fat composition is also compromised. It is possible that a 
longer exposure (more than 20 weeks) to the treatment would have produced 
differences in weight and histological findings in the liver. 
 
In a previous study (138) 129S2/SvPas mice that had been assigned to either low GI 
diet or high GI diet for 25 weeks had the same total body weight, but the high GI 
group had significantly greater body fat mass and altered hepatic fat storage. It is 
possible that these mice were more ‘carbohydrate and fat sensitive’ than the obesity-
prone C57BL/6 mice used in our study. It is also possible that the additional 5 weeks 
of exposure to the diet might have been a factor that influenced the timing of 
appearance and accumulation of hepatic fat deposition.   
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Some findings should be noted. Our study suggests there is a tendency for higher 
prevalence of diffuse strong staining (score 3, indicative of greater glycogen 
deposition) in CC, HC and HH groups (more than a third of the samples were 
affected) compared to LC and LL.  In contrast, 75% of LL had no or only pale focal 
staining, while ~60% of LC had diffused moderate staining. Overall, these results 
imply that an exposure in utero or beyond to either chow or a high GI diet increases 
glycogen deposition in the liver.  This is itself is not pathological but provides 
additional evidence that the high GI diet did indeed increase postprandial glycaemia 
and/or insulinaemia.  Similarly, evidence of moderate lobular necrosis, was noted in 
the HH group (40% were affected) while LL pups had either no or light signs. This 
could indicate that continuing life-long exposure to a high GI diet increases the risk 
of pathological changes in the liver. 
 
These findings are consistent with those of an observational study in humans that 
investigated the relationship of liver steatosis to dietary GI (258). The prevalence of 
high grade liver steatosis increased significantly across the ranges of dietary GI 
(from low to medium to high). The high grade steatosis in the subjects of the high GI 
diet was twice as frequent as in the low or medium GI diet subjects, even though 
there were no differences in BMI between the subjects. 
 
The limitations of our study should be noted.  In particular for this part of the study 
we could obtain only a small number of liver samples, particularly for the HH and 
LL diet groups. This was due to the small population of pups in each diet group (~10 
pups/groups) and also to difficulties with the collection of the samples. It would be 
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desirable to repeat the study with a greater number of animals so that the power of 
the study is adequate for the purpose of liver histology.  
 
In summary, despite interesting trends, the histological findings of this study do not 
show a definitive effect of the GI of the maternal and offspring’s diet on liver tissue 
morphology. Further studies on a greater number of liver tissues in both older and 
young animals are warranted.  
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Chapter 6 General discussion and conclusions 
This research project investigated the effect of two carbohydrate-modified diets 
during the critical period of in-utero development. Our hypothesis was that a 
maternal diet containing quickly digested vs. slowly digested starch would have 
adverse outcomes on metabolic markers and expression of key genes that increased 
the risk of offspring obesity. In male offspring of high vs. low GI C57BL/6 female 
mice, we studied effects on growth rate, food intake, glucose and insulin tolerance, 
and other markers of metabolism. Simultaneously, we obtained data on the 
expression of the Fto gene in the hypothalamus, adipose and muscle tissues, liver 
and placenta. We also determined leptin gene expression in visceral adipose tissue 
and other genes involved in regulation of appetite and energy homeostasis (AGRP, 
NPY, POMC, CART and LEPR) in hypothalamic tissue. Finally we examined liver 
histology for signs of differences arising from different maternal diets. The study 
design allowed for observations of both early-life and life-long exposure in response 
to the two carbohydrate-modified diets.  
 
To our knowledge, this is the first study to examine the direct effects of maternal and 
life-long exposure to high vs. low GI feeding on Fto and leptin gene expression in 
offspring.  Table 6.1 summarises the most important associations we were able to 
detect in relation to an exposure to a high vs. low GI diet. Here we highlight and 
interpret the findings in the context of the current scientific literature.  
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Table 6.1 Significant associations of early-life and life-long exposure to a low GI 
diet. For the effect of early life exposure, offspring of low GI-fed mothers were 
switched over to a chow diet after weaning at 4 weeks of age (LC group). The life-
long exposure effect was obtained in offspring that continued a low GI diet until 20 
weeks of age (LL group).  The comparison group in each case is the high GI-fed 
group (HC and HH respectively).  
 
Nutritional exposure Associations 
Early-life exposure 
to a low GI 
associated with: 
 
 ↓ FTO in placenta  
 ↑ FTO in white muscle 
 ↓ FTO in red muscle 
 ↑ Leptin in VAT 
 ↓ AGRP in hypothalamus 
 ↓ POMC in hypothalamus 
 ↓ CART in hypothalamus 
 ↓ LEPR in hypothalamus 
 
Extended exposure 
to a low GI 
associated with: 
 
 ↓ FTO gene expression in hypothalamus 
 ↑ FTO expression in white muscle 
 ↓ FTO expression in red muscle 
 ↑ Leptin expression in VAT 
 ↑ Leptin expression in SAT 
 ↓ NPY expression in hypothalamus 
 ↓ plasma ghrelin 
 ↑ plasma leptin 
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6.1 Outcomes on phenotype and metabolic parameters 
Our first hypothesis was that glucose tolerance and insulin sensitivity in the 
offspring of low GI-fed mothers would be higher than those of high-GI-fed mothers. 
In the current study, however, these parameters were not affected by either early-life 
nor life-long exposure to the diets. Therefore, our findings do not support our initial 
assumption. Similarly, we were not able to show a difference in food intake, growth 
or body weight between the groups. High and low GI diets have produced 
differences in phenotype in some human studies, with high GI diets being associated 
with a higher degree of fatness and higher body weight (128, 131, 259-261). 
Similarly, many (but not all) studies in animal models have produced differences in 
body fat, glucose tolerance and/or insulin resistance (175, 178, 262, 263). Pawlak et 
al., for example, using partially pancreatectomised pair-fed rats, reported no 
differences in growth rate or body weight, but significant differences in body 
composition, glucose tolerance and insulin sensitivity (135). Mice on the high-GI 
diet, however, had almost twice the body fat of those on the low GI diet after 9 
weeks (135, 136). The use of pancreatectomised animals was the key because beta-
cell mass is reduced, increasing the risk of impaired glucose tolerance and its 
metabolic sequalae.   
 
Nutritional regimes (especially in rodents) on the association of the GI with body 
fatness often address other macronutrient issues at the same time, such as high vs. 
low fat, or high vs. low protein (175, 262, 263). We propose that using a higher fat 
content in our high and low GI feeds may have produced the expected differences in 
phenotype.  Previous studies have indicated that fat is the crucial stimulus for 
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overconsumption, obesity and diabetes-related parameters in C57BL/6 wild-type 
mouse (175, 176).  
 
In the high and low GI diets used here, the percentage of energy from fat was 7%, 
whereas for the chow diet it was 4.6%.  In studies where the focus of the treatment 
diets is the fat content, any percentage below 11% is considered a low fat diet and 
above 50% is a high fat diet (175). Therefore, we can confidently say that the diets 
we used in the present study were low fat diets and this could have compromised the 
ability to show phenotypical differences between the groups.   
 
In addition, the in vitro testing allowed us to test and confirm that the two 
commercial high and low GI diets contained starches with different rates of digestion.  
Since rapidly available glucose in the best predictor of glycaemic response in 
humans, it was likely that the high GI feed would have produced a higher 
postprandial glucose response. However, this testing does not necessarily translate to 
the glycaemic impact in animals after consumption, and it is possible that the 
absolute GI difference between the two feeds was not big enough to produce 
different effects on phenotype.  
 
We also anticipated the concentration of circulating hormones involved in the 
regulation of appetite and satiety would have been differentially influenced by 
exposure to the two treatment diets. We showed that life-long exposure to a low GI 
diet was associated with a 6-fold greater fasting plasma leptin and 2-fold lower 
ghrelin (LL vs. HH). Even though we were not able to show a significant impact on 
ghrelin and leptin levels in the early-life exposed pups (LC vs. HC), the data showed 
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a consistent and similar trend to that observed in the life-long exposed pups (LL vs. 
HH). Thus we argue that in both cases, early-life nutrition appears to play an 
important predisposing role. The high glycaemic exposure during the gestational 
period has therefore produced subtle effects that appear to be exaggerated after 
extended exposure.  
 
The concurrent use of a chow diet as a reference, allows us to conclude the two 
carbohydrate-modified diets produced responses that fell within the typical range 
expected of C57BL/6 mice.   Chow diets, however, are not standardised and may 
vary in glycaemic impact because ingredients vary from time to time, as well as from 
manufacturer to manufacturer.  The lack of information on the GI of the chow diet 
precludes further assumptions on the extent to which the diet after weaning affects 
phenotype.  
 
We found no significant differences in the other hormones measured in fasting 
plasma samples (adiponectin, insulin, PYY, GLP-1, PP, ACTH, IL6 and TNFɑ). As 
discussed previously, we may have seen differences if they were accompanied by an 
overweight phenotype. Therefore, in view of this limitation, future research in this 
arena should consider the use of animal feeds from raw materials of a known GI 
value, and pre-tested in trained meal-fed animals. This would provide a clearer 
picture on the effect of maternal and later life exposure to a high vs. low GI diet. In 
addition, we recommend the use of feeds with a higher fat content in order to aim for 
phenotypical differences. Data should then be collected both before and after the 
phenotype appears. The recent landmark study by Solon-Biet and colleagues (264) 
demonstrates the importance of interactions of fat, protein and carbohydrate energy 
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for long term health, longevity and body composition in the C57BL/6 mouse. Their 
findings should therefore guide the decision on the composition of the two treatment 
diets. Ideally, the macronutrient (fat, protein and carbohydrate) composition of the 
feed should also be fine-tuned so as to produce an animal with some degree of 
excess adiposity. 
 
6.2 Effects of gene expression 
Our next hypothesis was that gene expression (Fto, leptin, AGRP, NPY, POMC, 
CART and LEPR) in key tissues would have been differentially regulated by the two 
treatment diets. This hypothesis was confirmed, demonstrating a likely epigenetic 
regulatory effect of the glycaemic impact of the diet on these genes.  
 
In particular, the results obtained on Fto gene were consistent and robust. Maternal 
exposure to a high GI diet from conception onwards was associated with ~4-fold 
higher Fto gene expression in the placental tissues recovered at late gestation. This 
suggests that postprandial maternal glycaemia within the normal range has a 
profound influence on metabolism of the placenta, including the expression of the 
Fto gene. Furthermore, life-long exposure to a high GI diet was associated with 2.5-
fold higher hypothalamic Fto mRNA expression. Although this trend was not 
evident in the early-life exposed pups, the findings in placenta as well as pups 
exposed for longer suggest early programming sets the scene for the future pattern of 
hypothalamic Fto gene expression. Since enhanced expression of Fto is associated 
with increased risk of obesity in rodents (83), the lower expression levels in such 
important tissues as the hypothalamus and the placenta suggest that a low GI diet can 
reduce the risk for obesity and associated disorders. 
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Likewise, the results we obtained on leptin gene expression were highly significant. 
Leptin mRNA levels in the visceral adipose tissue were >3-fold higher in the low 
GI-fed groups (both early-life and life-long exposure) than in the high GI-fed 
offsping. This, together with the results on fasting plasma leptin levels (6-fold higher 
in life-long exposed pups) and in parallel with the fact that these mice did not display 
phenotypical differences, suggests that the leptin differences are primary outcomes 
and not secondary to increased body weight, insulin resistance or glucose intolerance. 
 
Although leptin is a major regulator of food intake and energy homeostasis, it is not 
the only one. Leptin exerts inhibitory feedback on anabolic hypothalamic peptides 
such as NPY and positive feedback on catabolic peptides such as POMC, the 
precursor of the melanocortin-3/-4 receptor agonist ɑ -melanocyte-stimulating 
hormone (265). When leptin central signalling is disrupted by genetic modifications, 
NPY expression increases and POMC expression decreases, putting the organism 
into an anabolic state, and increasing the risk of developing obesity (265). So it 
could be predicted from an examination of the hypothalamic NPY and POMC 
expression, that in the low GI mice (LC and LL) mRNA NPY levels would be lower 
and POMC higher, reducing the risk of obesity. The opposite effect would be 
expected for the high GI groups (HC and HH) since their leptin gene expression in 
the VAT was significantly lower. 
 
Indeed, there was a clear trend for NPY gene expression in the hypothalamus. There 
was ~3-fold lower NPY mRNA expression level in the LL group, and we observed a 
similar trend in the LC group. This implies a reduced risk of obesity. However, the 
results on POMC expression were puzzling.  POMC mRNA expression in LC was 
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significantly lower than HC, suggesting lower levels of POMC in the circulation and 
increased risk of obesity. No differences were observed between the long-life 
exposed groups (HH and LL). 
 
Overall, however, there are much greater absolute differences in the expression of 
orexigenic genes, AGRP and NPY in HH vs. LL, with no significant differences in 
the anorexigenic genes, POMC and CART.  This implies greater anabolic effects and 
greater risk of obesity as a result of life-long exposure to a high GI diet vs. low GI 
diet. The findings confirm that the source of carbohydrate has important epigenetic 
and/or programming effects on the developing hypothalamus, but the net result on 
appetite and energy balance is difficult to predict. 
 
Taken together, our novel findings provide molecular insights into how differences 
in carbohydrate nutrition, particularly the rate of digestion and/or maternal post-
prandial hyperglycaemia, provoke differences in the regulation of the expression of  
obesity associated genes as well as regulation of orexigenic and anorexigenic genes 
in the brain’s appetite centre, the hypothalamus.  Thus, epigenetic changes are a 
potential mechanism that underlines the observed changes in gene expression in the 
present study and need to be further investigated in future studies. 
 
Other genes should also receive attention in the context of maternal dietary 
carbohydrate. Godfrey and colleagues showed that higher methylation of the retinoid 
X receptor-(RXRA) on chromosome 9, was associated with fat mass and % fat 
mass in two cohorts of British children (266).  Interestingly, the degree of 
methylation was also linked to lower maternal carbohydrate intake in early 
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pregnancy and higher neonatal adiposity in this population. Thus epigenetic studies 
on the degree of methylation or histone modification on genes such as RXRA will 
provide a more in depth understanding of the how the quality of carbohydrate 
regulates influences the risk of obesity. 
 
Recent research has also identified a novel gene located in the broad neighbourhood 
of FTO called Iroquois homeobox protein 3 gene (IRX3) (52). IRX3 encodes a 
transcription factor involved in regulating the expression of other genes (including 
FTO) which is highly expressed in the brain, and consistent with a role in regulating 
energy metabolism and eating behaviour. Although IRX3 is located far from FTO 
gene, the researchers showed that the obesity-associated regions in FTO were 
physically in contact with the promoter of IRX3. Mice lacking the IRX3 gene 
weighed 25–30% less than mice with a functional IRX3 gene and did not gain 
weight on a high-fat diet and were resistant to metabolic disorders such as diabetes. 
In view of these findings, it would be informative to determine IRX3 expression in 
future research.  
 
6.3 Histological findings 
In the present study, despite interesting trends, the histological findings did not show 
a definitive effect of the GI of the maternal and offspring’s diet on liver tissue 
morphology. Thus our hypothesis that a high GI diet consumed in pregnancy or 
beyond increases the risk of liver pathology in the offspring, is not supported.  
 
However there was a tendency for higher prevalence of diffuse strong glycogen 
deposition in CC, HC and HH groups (more than a third of the samples were affected) 
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compared to LC and LL. Overall, these results imply that an exposure in utero or 
beyond to either chow or a high GI diet increases glycogen deposition in the liver. 
This in itself is not pathological but provides additional evidence that the high GI 
diet did indeed increase postprandial glycaemia and/or insulinemia.   
 
For the purpose of liver histology the study needed a greater number of samples. A 
future study on the effects of maternal high vs. low GI diet on liver histology should 
include a greater number of samples to increase the statistical power of the outcomes. 
 
6.4 Summary of the effect of prenatal exposure to the low GI diet 
The findings of the present study are novel and provide a unique first approach of the 
effects of low GI diet during the prenatal period and lactating period. We show that 
FTO gene expression was 4-fold lower in the placentas of the low GI-fed mothers. 
Though placental programming by dietary manipulation is not yet widely researched 
and understood, animals studies on adaptations in placental phenotype have been 
observed in response to severely restricted dietary manipulations, and showed a 
reduction of the nutrient transfer capacity of the placenta (104). And in diabetic 
pregnancies, studies show that maternal gestational hyperglycemia may be involved 
in the pathogenesis of IR, impaired glucose tolerance, type 2 diabetes mellitus, the 
Metabolic Syndrome and subsequent cardiovascular diseases in adult offspring. A 
low GI maternal diet rather than a low carbohydrate diet, has been associated with 
measurable benefits to the offspring such as fetal and placental insulin and glucose 
regulation, fetal growth, birth weight and offspring adiposity (131, 133, 210).   
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Therefore, the differences in Fto gene expression in the placenta observed in the 
present study suggest that postprandial glycaemia, rather than the dietary 
carbohydrate content, is the mechanism that regulates placental gene expression.  
 
We also show that Fto gene expression was higher in the white muscle and lower in 
the red muscle, indicating the possibility that carbohydrate quality during gestation 
can differentially influence the expression of genes in the muscle, in a way 
dependant to the nature and function of the particular muscle type. Furthermore we 
show that leptin gene expression in the visceral adipose tissue was 4.4-fold higher in 
the pups exposed to a low GI diet early in life. We assume that this high leptin gene 
expression in the low GI fed offspring results in higher leptin protein production and 
therefore greater satiety, and over the longer term, has the potential to reduce the risk 
of excessive food intake and obesity.   
 
Finally, our findings indicate that the offspring of low GI mothers display important 
differences in expression of key hypothalamic appetite-regulating genes such as 
AGRP, POMC, CART and LEPR. This shows that the well recognised co-
expression of AGRP/NPY and POMC/CART is regulated by the nature of the 
dietary carbohydrates and therefore, differences in carbohydrate nutrition, including 
rate of digestion and/or maternal post-prandial hyperglycaemia can provoke 
differences in the regulation of orexigenic and anorexigenic genes in the 
hypothalamus. We propose that the source of carbohydrate has important epigenetic 
or programming effects on the developing hypothalamus, but the net result on 
appetite and energy balance is difficult to predict.   
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6.5 Strengths and weaknesses of this study 
The strengths of our study include the use of an animal model which allowed us to 
observe the early in-utero impact of the maternal diet on the expression of Fto and 
leptin genes in prenatal tissue (the placenta) and in adult tissues of the offspring. 
This is a valuable tool which brings power to the early programming theory. 
Furthermore, the fact that the treatment diets were identical apart from the source of 
the carbohydrate allows us to separate the effect of quantity of carbohydrate and 
other macronutrients from the quality of carbohydrate.  The in vitro starch digestion 
we conducted on the commercial feeds confirmed that the rate at which glucose from 
each diet becomes available for absorption varied according to their GI. This 
reinforces the results obtained as it demonstrates it is the quality of carbohydrate and 
not the amount that has an epigenetic impact.  
 
The weaknesses of our study should be noted. The biggest limitation is the use of a 
mouse model to test our hypotheses. It cannot be assumed that human offspring will 
display similar up-regulation of FTO in response to differences in the GI of maternal 
diet. Mice have evolved along a different evolutionary pathway with different native 
diet to humans. As an alternative, non-human primates could be employed although 
this would be expensive and difficult to undertake with large numbers of animals. 
Likewise, as humans, we consume real foods and mixed meals, and rarely do we 
consume a diet that has been manipulated in carbohydrate alone as was the case in 
the present study. Also, body composition measurements (total body fat, epididymal 
fat) and tissue/organ weights of the pups would have provided important insights and 
better understanding of some of the outcomes in the present study. However, we 
placed the highest priority on extracting and snap-freezing all the tissues as fast as 
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possible to increase the reliability of the gene expression studies.  Finally, we need to 
consider that an exposure to an obesogenic diet post weaning, as we can considered 
the High GI, is required to bring out programmed phenotypes characterised by 
obesity related indicators. 
 
6.6 Significance of this study 
Obesity is a complex metabolic disease that is characterised by the interaction of 
obesity susceptibility gene variants with diet composition and other environmental 
factors. The investigation of gene–diet interactions is becoming increasingly 
important in the attempt to understand the etiology and pathophysiology of nutrition-
related disorders. The knowledge that some macronutrients can interact with obesity-
associated genetic variants presents the opportunity for more effective preventative 
intervention and provides the basis for personalised nutrition therapy that will more 
effectively address the current epidemic of obesity. 
 
The definition of functional foods is not universal but the most common one is: 
“foods or dietary components that may provide a health benefit beyond providing 
basic nutrition” (19). Nutrition and food science are making rapid advances. Only 25 
years ago, the brain was believed to be insulin-insensitive, but today it is widely 
accepted that insulin is a central regulator of neural function and hippocampal 
metabolism, and a key player in multiple neuropsychological conditions (267). 
Today, our carbohydrate foods are more likely to be highly processed (or even ultra-
processed), more finely milled, “instantised”, and separated from natural components 
such as fibre that act as a barrier to slow enzymic digestion. The quality of 
carbohydrate in the human diet has therefore undergone a rapid change that dictates 
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marked increases in postprandial glycaemia and insulinaemia. Hence a low GI diet, 
by improving postprandial glucose homeostasis and insulin action throughout life, 
represents an inexpensive, safe and realistic alternative in the context of 
behaviourally sustainable nutrition. During pregnancy it has the potential to 
epigenetically program the offspring to lower the risk of obesity and metabolic 
disorders. The choice of low GI carbohydrates therefore has not only a therapeutic 
basis, but one that is without the inherent risks associated with lower carbohydrate, 
higher protein and higher fat diets (268).  
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                   Appendix 1 
Associations between variants of the FTO gene and obesity traits 
(BMI, waist circumference/ waist–hip ratio, fat percentage/ fat mass) 
 
FTO variant Associated trait 
rs1558902 BMI 
rs1121980 BMI 
rs1558902 BMI, WAIST 
rs9939609 BMI, Waist 
rs8050136 BMI, Fat % 
rs17817449 BMI, Fat %, WAIST 
rs12149832 BMI 
rs1421085 BMI, Fat %, WAIST 
 
Table adapted from: 1) Fall T, Ingelsson E. Genome-wide association studies of 
obesity and metabolic syndrome. Molecular and Cellular Endocrinology 201; 
382(1): 740–757. 2) Sebert S, Salonurmi T, Keinänen-Kiukaanniemi S, Savolainen 
M, Herzig K, Symonds M, Järvelin MR. Programming effects of FTO in the 
development of obesity. Acta Physiologica 2014; 210(1): 58-69. 3) Loos R, Yeo G. 
The bigger picture of FTO: the first GWAS-identified obesity gene. Nature 
Reviews Endocrinology 2014; 10, 51–61. 
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Appendix 3 
Summary of adverse and unexpected event 
On 25th February 2011 we noticed 4 dead pregnant female mice. Mice seemed fine 
for the majority of the time before the event but the last 2 -3 days started losing 
weight and unexpectedly died. The same happened with other female pregnant or 
lactating mice in the following weeks. All mice (females and males) were monitored 
daily and weights were taken regularly. No other symptoms were observed except a 
rapid weight loss.  
 
From the first event, the veterinary doctor was contacted and a post mortem 
examination was conducted. Together with the dead lactating females, all pups were 
culled due to starvation.  From the 16 female adult mice, 7 were found dead. All 
male mice (n=8) survived. The mice were initially divided into 2 groups following 
either a low glycaemic or a high glycaemic irradiated diet. Trio breeding was used 
according to the approved protocol. On 8th March, the protocol was terminated and 
after consultation with the vet, all mice changed to a chow diet with addition of a 
vitamin supplement and a hydration gel, to monitor developments.  From that day 
onwards, mice were looking better and gaining weight. Nevertheless, mice that 
survived were still excluded from the protocol and given to other researchers for 
different projects.  
 
The outcomes of the post mortem examination and the veterinary doctor’s report 
were as follows: “Post mortem examinations were conducted on lactating females 
exhibiting weight loss and pups from affected mothers. Histological examination of 
a wide range of organs revealed occasional mild to moderate lesions in a small 
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proportion of tissues in the mothers but these were not consistent; there were no 
significant abnormalities in the pups. Serological tests for 14 infectious agents were 
negative and haematological assessment of one mother was unremarkable. 
 
Despite comprehensive investigation, there were no findings that pointed to a 
specific cause for this problem. There are, however, several features of the case 
which suggest an association with the specially formulated diets. These include the 
recovery of the animals following reinstatement of standard diet and the fact that no 
similar problems were observed in other animals on standard diet elsewhere in the 
facility during the time of the illness. 
 
After discussion with the manufacturer of the specialty diets, it was established that 
both diets contained the same raw materials as diets supplied to other customers 
around the same time, none of whom had reported problems. It is also worth noting 
that most of the ingredients in these diets are human food grade so should be of high 
quality.  
 
The one suspect factor here appears to be the use of irradiation to decontaminate the 
feed. Irradiation is used widely for this purpose and since it is known that certain 
vitamins can be partially broken down during the irradiation process, many standard 
rodent diets are fortified with key nutrients to prevent deficiency. In the present case, 
however, the diets were based on a special dietary formula (AIN-93G) developed for 
nutritional studies. While this formula is designed to meet the increased nutritional 
demands of pregnancy and lactation, it is not fortified to make up for possible losses 
during treatments such as irradiation. The fact that only lactating females developed 
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any detectable illness suggests that any nutrient losses due to the irradiation would 
only be marginal since the males (which of course were not facing the same 
nutritional demands as the lactating females) remained healthy. 
 
It is also at least theoretically possible that the irradiation treatment had induced the 
formation of toxic oxidation products in the feed. If this had been the case, however, 
one would have expected both sexes to be affected; it would also be expected that a 
similar effect would occur when standard diet is irradiated but the widespread and 
successful use of irradiated standard diets not support this. It is also believed that 
toxic oxidation products are more likely to be a problem in diets containing much 
higher levels of fat that is the case with the diets in this case. 
 
In conclusion, I believe there is strong circumstantial evidence that this outbreak was 
the result of a nutritional deficiency induced by nutrient loss during irradiation of the 
feed. Unfortunately, confirmation by nutrient assay is not feasible due to technical 
complexities and lack of sufficient quantities of specimen for analysis.” 
 
In view of the above findings, in collaboration with the vet and after consulting 
researchers in other universities doing similar work, we retained that the low and 
high GI diets were damaged during the irradiation and therefore many nutrients 
important for pregnancy and lactation e.g. folate, vitamin A, were lost or 
significantly decreased. This could have led to insufficient nutrient intake from the 
female pregnant and lactating mice. Our next action was to restart the protocol with 
new mice using a new batch of the low GI and high GI diets that was not irradiated. 
The diets were ordered from Australia (Specialty Feeds) and thus the risk of bacterial 
- 218 - 
 
infection was minimized. While it was important to consider the contamination risks 
posed by non-irradiated feed in animal facilities, these risks were greatly reduced 
with the sort of semi-pure custom diets used in the present study since they were 
based on human food grade ingredients. Furthermore, non-irradiated special diets 
were used in other animal facilities for some years without evidence of infection 
being introduced. The new trial started in October 2011. 
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Appendix 4 
List of chemicals 
• Amyloglucosidase (Megazyme International Ireland Ltd. Bray Co., Ireland)  
• Chloroform (Sigma-Aldrich) 
• Eosin 
• Ethanol (200 proof) (Sigma-Aldrich) 
• Fast SYBR® Green Master Mix (Applied Biosystems) 
• Formaldehyde (37% (w/v)) (Sigma-Aldrich) 
• Glucose oxidase-peroxidase (Megazyme International Ireland Ltd. Bray Co., 
Ireland) 
• Haematoxylin 
• Insulin (Actrapid Novo Nordisk Pharmaceuticals Pty Ltd) 
• Isopropanol (Sigma-Aldrich) 
• Multiplex Map Kit by Cardinal Bioresearch Pty Ltd (New Farm, Qld, 
Australia) 
• Oligonucleotides (Sigma Genosys, Sigma-Aldrich) 
• Porcine pancreatic α-amylase (Sigma-Aldrich)  
• QIAzol™ lysis reagent (Qiagen) 
• RNeasy Lipid Tissue Mini Kit (Qiagen) 
• RNeasy Mini Kit (Qiagen) 
• Superscript® VILO™ cDNA Synthesis Kit (Life Technologies, Australia)  
• Xylene  
